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ABSTRACT 
Weina Zhao 
 
Tip110 Control of HIV-1 Gene Expression and Replication 
 
Transcription and alternative splicing play important roles in HIV-1 gene expression and 
replication and mandate complicated but coordinated interactions between the host and 
the virus.  Studies from our group have shown that a HIV-1 Tat-interacting protein of 
110 kDa, Tip110 synergies with Tat in Tat-mediated HIV-1 gene transcription and 
replication.  However, the underlying molecular mechanisms were not fully understood 
and are the focus of the dissertation research.  In the study, we first demonstrated that 
Tip110 bound to unphosphorylated RNA polymerase II (RNAPII) in a direct and specific 
manner.  We then showed that Tip110 was detected at the HIV-1 long terminal repeat 
(LTR) promoter and associated with increased phosphorylation of serine 2 within the 
RNAPII C-terminal domain (CTD) and increased recruitment of positive transcription 
elongation factor b (P-TEFb) to the LTR promoter.  Consistent with these findings, we 
demonstrated that Tip110 interaction with Tat directly enhanced transcription elongation 
of the LTR promoter.   
 
During these studies, we also found that Tip110 altered HIV-1 mRNA alternative 
splicing and increased tat mRNA production.  Subsequent analysis indicated that 
Tip110 selectively increased tat exons 1-2 splicing by activating HIV-1 A3 splice site but 
vi 
 
had no function in tat exons 2-3 splicing.  We then showed that the preferential splicing 
activity of Tip110 resulted from Tip110 complex formation with hnRNP A1 protein, a 
negative splicing regulator that binds to the ESS2 element within tat exon 2, and as a 
result, blocked the complex formation of hnRNP A1 with ESS2 and subsequently 
activated HIV-1 A3 splice site.  Taken together, these results show that Tip110 
functions to regulate HIV-1 transcription elongation and HIV-1 RNA alternative splicing.  
These findings not only add to our understanding of Tip110 biology and function but also 
uncover a new potential target for development of anti-HIV intervention and therapeutic 
strategies. 
 
 
 
                                                Johnny J. He, Ph.D., Chair 
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INTRODUCTION 
 
1. HIV-1 AND THE AIDS PANDEMIC 
 
1.1 HIV-1 pandemic 
The acquired immunodeficiency syndrome (AIDS) has become a global epidemic.  
AIDS and its etiologic agent, HIV-1 were first identified in the early 1981.  Since then, 
there are more than 20 million people including 330,000 children have been killed.  
According to the most recent report on the global AIDS epidemic 2009 from the United 
Nations, about 34 million people were living with HIV at the end of 2008, in which there 
were 2.7 million new HIV infections and 430000 newly-infected children under 15.  In 
2008, there were 2 million AIDS-related deaths, 280000 of them were children.  The 
report also indicates that about 17 million people, close to half of the HIV-1 infected 
people, are women, suggesting that there could be more babies acquiring infection from 
their HIV-1 positive mothers through pregnancy, delivery or breast feeding.  Moreover, 
use of highly active anti-retroviral therapy (HAART) and subsequent improved survival 
of HIV-infected individuals also add to the total number of HIV-1-infected people 
worldwide. 
 
1.2 Clinical course of HIV-1 infection 
The clinical course of HIV-1 infection starts with some acute flu-like syndrome, which 
last for 6 to 12 weeks (Lyles, Munoz et al. 2000; Douek, Picker et al. 2003; Alam, 
Scearce et al. 2008).  The patient usually experiences fever, rash, swollen lymph glands, 
headache, gastrointestinal symptoms and weight loss, but none of these is life-threatening.  
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At this stage, there is an initial fall in the number of CD4+ cells and a rise in CD8+ cells 
but both cells quickly return to normal level (Douek, Brenchley et al. 2002; Guadalupe, 
Reay et al. 2003).  Virus titers can be very high at this stage and could reach one 
hundred million virus particles per milliliter of plasma.  Following the initial infection, 
potent humoral and cellular responses will have the viral replication under control and 
reduce the virus titer.  The infected individual enters the clinical latency stage; this stage 
lasts many months and years.  At this stage, HIV is present within lymphoid organs, 
mainly trapped in the follicular dendritic cells (FDC) (Douek, Picker et al. 2003).  When 
latency infected cells are activated, HIV-1 replication resumes and CD4+ lymphocytes in 
the peripheral blood exhibit steady decline.  When the CD4+counts decrease below 200 
per microliter, the individual enters the clinical AIDS stage of disease (Leng, Borkow et 
al. 2001; Brenchley, Price et al. 2006).  In this final stage, cell-mediated immunity is lost, 
there are a variety of opportunistic infections (Pantaleo, Graziosi et al. 1993).  Infected 
individuals usually die from HIV-associated diseases.  Nevertheless, host factors such as 
age or genetic differences and the virulence of different viral strains play important roles 
in the rate and severity of AIDS disease progression (Fauci 1993; Pantaleo, Graziosi et al. 
1993).  
 
1.3 HIV-1 and its genome 
HIV is a complex retrovirus with a 9.2 kb genome. It encodes nine open reading frames 
(ORF) and three of these ORF are common to all retroviruses: gag, pol, and env (Fig. 1).  
Gag provides the basic structural component of the virus; it encodes four structural 
proteins that make up the core of virion: matrix protein (MA, p17), capsid protein (CA, 
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p24), nucleocapsid protein (NC, p7 and p6).  Env encodes for gp160, the precursor of 
gp120 and gp41.  These envelope proteins are embedded in the outer layer of the virions 
and enable the virus to attach and fuse with host cells. Pol codes for three viral enzymes, 
including protease (PR), reverse transcriptase (RT), and integrase (IN).These proteins 
provide essential enzymatic functions and are encapsulated within the virion particle.  
HIV also has 6 unique regulatory genes: tat, rev, nef, vpu, vpr, and vif.  Vif, Vpr, and 
Nefproteins are packaged in the viral particle and important for HIV-1 infectivity and 
virion production.  Two other accessory proteins, Tat and Rev provide essential 
regulatory functions.  Tat protein is a transactivator for HIV-1 transcription.  It interacts 
with trans-activating responsive (TAR) structure of HIV-1 RNA, recruits positive 
transcription elongation factor b (P-TEFb) to the transcription complex and enhances the 
transcription elongation step (Frankel and Young 1998).  Rev functions to export singly 
spliced and unspliced RNA from the nucleus to the cytoplasm (Malim, Hauber et al. 
1989).  The last protein, Vpu, indirectly assists in assembly of the virion (Neil, Zang et 
al. 2008).  Besides these 9 ORF, there are other important non-coding RNA elements 
located within the HIV-1 genome, including R: a short sequence at the 5’ and 3’ ends; U5, 
a unique sequence at the 5’end; PBS: primer binding site that serves as the initiation site 
for minus strand RNA synthesis; Ψ: the recognition site for packaging viral RNA into 
particles; PPT: the polypurine tract that provides the primer for synthesis of the plus 
strand DNA; U3, a unique sequence at the 3’ end.  When HIV-1 proviral DNA is 
integrated into chromosome DNA, U3, R and U5 are duplicated at both ends of DNA and 
make up the long terminal repeat (LTR) (Frankel and Young 1998).  
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1.4 HIV-1 life cycle 
HIV-1 infection of a susceptible cell begins with interaction of the envelop 
glycoproteinsgp120 with both CD4 (Fig. 2) (Alkhatib, Combadiere et al. 1996; Feng, 
Broder et al. 1996).  Following high-affinity attachment of gp120 to CD4, the envelope 
complex undergoes a structural change, which exposes the chemokine binding domains 
of gp120 and allows them to interact with the chemokine receptor CCR5/CXCR4.After 
the virus enters into the target cell, the viral core is uncoated.  One enzyme called 
reverse transcriptase liberates the single-stranded (+) RNA from the attached viral 
proteins and converts the viral RNA into dsDNA.  Then, dsDNA enters the nucleus and 
becomes integrated into the genome by the action of another viral enzyme integrase (IN).  
Using the integrated viral DNA as a template, viral RNA is synthesized from the LTR 
promoter by the cellular enzyme RNAPII and a number of other cellular and viral factors 
(Berkhout, Silverman et al. 1989; Laspia, Rice et al. 1989).  Completely spliced RNA 
transcripts are then exported to the cytoplasm and translated into the regulatory proteins 
Tat, Rev and Nef.  Rev is imported into nucleus and facilitates nuclear export of singly 
spliced and unspliced viral RNA, while Tat transactivates to produce full-length viral 
RNA (Malim, Bohnlein et al. 1989; Malim, Hauber et al. 1989).  Structural proteins Gag 
and Env are produced by full-length mRNA.  The Env polyprotein is cleaved by cellular 
protease into two gp41 and gp120 and then transported to the plasma membrane.  The 
Gag and Gag-Pol polyproteins interact with the inner surface of the plasma membrane 
and with HIV genomic RNA to form virions, followed by budding out of the host cell.  
HIV protease (PR) cleaves the Gag and Gal-Pol polyproteins into individual HIV  
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Figure 1. HIV-1 genome Organization of and virion  HIV is a complex retrovirus 
with a 9.2 kb genome.  It encodes nine open reading frames (ORF) and three of these 
ORF are common to all retroviruses: gag, pol, and env.  Besides these, HIV has 6 
unique regulatory genes: tat, rev, nef, vpu, vpr, and vif.  
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structural proteins and enzymes.  Finally, the virions mature and become infectious to 
begin a new round of infection. 
 
2. 
 
HIV-1 TRANSCRIPTION AND REGULATION 
2.1 HIV-1 basal transcription 
The HIV-1 basal transcription begins from the 5’ LTR promoter and does not have the 
involvement of HIV-1 Tat protein.  It is accomplished by a complex network of 
interactions between cis-elements and trans-acting factors.  These cis-acting regulatory 
sites are located in the 5’ LTR.  The HIV-1 LTR is generally divided into four 
functional domains: TAR, the core promoter region, the enhancer region, and the 
regulatory region.  The core promoter resembles that of many eukaryotic genes, 
containing a TATA box and three tandem Sp1 sites (Mallardo, Dragonetti et al. 1996; 
Stevens, De Clercq et al. 2006).  The Sp1 sites recruit transcription factor Sp1 that is 
expressed in most eukaryotic cells and is critical for both basal transcription and 
Tat-mediated transactivation.  The TATA box facilitates the binding of transfection 
factor IID (TFIID) and transcription factor IIA (TFIIA) to the LTR.  The HIV-1 
enhancer region consists of two tandem binding sites for transcription factor NF-kB, 
which function as the principal enhancers of transcription and are required for basal 
transcription (Benjamin Berkhout 1992; FATAH KASHANCHI 1994; Carlos Sune 1995).  
The basal level of transcription leads to produce stable, short, and nonpolyadenylated 
transcripts.  These short transcripts are RNA of 60 bp containing heterogeneous 3’ ends 
and TAR element (Harrich, Garcia et al. 1989; Perkins, Agranoff et al. 1994). 
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Figure 2. HIV-1 life cycle  1. Binding of gp120to CD4 and CXCR4 or CCR5; 
2.Membrane fusion between virus and cells; 3. Viral core uncoating; 4.Reverse 
transcription of the genomic ssRNA into dsDNA provirus; 5.Nuclear importation of the 
pre-integration complex; 6.Provirus integration into the host chromosome; 7. 
Transcription and alternative splicing of HIV-1 mRNA; 8.Translation of structural 
proteins and viral enzymes; 9.Virion assembly at the cell membrane; 10.Virion budding 
and maturation 
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2.2 N-TEF 
The negative transcriptional elongation factors (N-TEF) are associated with RNAPII and 
causes transcription pausing.  N-TEF arrest RNAPII at nucleotides 20-50downstream 
from the initiation site, resulting in the accumulation of short transcripts (Wu, Yamaguchi 
et al. 2003; Wu, Lee et al. 2005). N-TEF includes the 5, 
6-Dichloro-1-beta-D-ribofuranosylbenzimidazol (DRB) sensitivity-inducing factor (DSIF) 
and the negative elongation factor (NELF) (Wada, Takagi et al. 1998; Yamaguchi, 
Watanabe et al. 1999).  DSIF is composed of Spt4 and Spt5, it is involved in HIV-1 Tat 
transactivation in vitro and contains many C-terminal repeats that can be phosphorylated 
by CDK9 in vitro (Fujinaga, Irwin et al. 2004; Ping, Chu et al. 2004).  NELF has four 
subunits: NELF-A, NELF-B, NELF-C and NELF-E.NELF-E contains RNA recognition 
motif (RRM) and interacts with the TAR element.  This binding is required for the 
inhibitory effect of NELF on transcription, which involves RNAPII pausing and 
decreased acetylation of histone H4 (Yamaguchi, Takagi et al. 1999).  DSIF and NELF 
bind to hypophosphorylated RNAPII complexes, while the hyperphosphorylation of the 
RNAPII CTD promotes dissociation of these negative factors from the complex and 
allows binding of other elongation factors (Lis 1998). 
 
2.3 P-TEFb 
The positive transcription elongation factor b (P-TEFb) is a cyclin-dependent kinase and 
controls the elongation phase of transcription by RNAPII.  During HIV-1 transcription, 
P-TEFb is the key regulator that helps RNAPII to overcome the rate-limiting step in the 
early stage of elongation and is an essential coactivator of the viral transactivator Tat.  It 
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is recruited to the TAR element by Tat and forms a stable RNA stem-loop at the 5’ end of 
the viral transcripts (Wei, Garber et al. 1998; Ammosova, Berro et al. 2006; Peterlin and 
Price 2006).  P-TEFb has two forms that have been referred as the large form and the 
free form (Michels, Fraldi et al. 2004; Barboric, Kohoutek et al. 2005; Li, Price et al. 
2005).  The free form contains CDK9 and cyclin T1 and has the kinase activity.  The 
large form contains CDK9, cylinT1, 7SK RNA and hexamethylene bisacetamide-induced 
protein1 (HEXIM1) or HEXIM2(Byers, Price et al. 2005; Egloff, Van Herreweghe et al. 
2006; Barrandon, Bonnet et al. 2007).  7SK snRNA and HEXIM1 keep P-TEFb in an 
inactivate state, but Tat competes with HEXM1 for binding to 7SK, blocks the formation 
of the 7SK/HEXIM1 complex, and releases P-TEFb from the pre-formed inactive form 
(Barboric, Kohoutek et al. 2005; Barboric, Yik et al. 2007; Li, Cooper et al. 2007; Sedore, 
Byers et al. 2007). 
 
There are two isoforms of Cdk9 in vivo: Cdk942 and Cdk955, which are generated by two 
different promoters in the Cdk9 gene (Shore, Byers et al. 2003; Shore, Byers et al. 2005).  
Cdk9 is a Cdc2-related kinase and phosphorylates the CTD of the largest subunit of 
RNAPII.  The phosphorylation of serine 5 (Ser 5) and serine(Ser2) of the RNAPII CTD 
is essential for the productive elongation of transcription (Marshall and Price 1992; Zhu, 
Pe'ery et al. 1997; Zhou, Halanski et al. 2000; Ramanathan, Rajpara et al. 2001; Shim, 
Walker et al. 2002).  Autophosphorylation of CDK9 confers the high affinity binding of 
the Tat:P-TEFb complex to TAR.  On the other hand, the Spt5 domain of DSIF and the 
E subunit of NELF can be phosphorylated and removed from TAR by CDK9, which 
leads to some reading-through transcription. Besides CDK9, Tat binding to cyclin T1 
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enhances its affinity for TAR RNA.  Tat binds to the cyclin domain of cyclin T1 in a 
zinc-dependent manner and requires specific residues within the Tat-TAR recognition 
motif of cyclin T1(Garber, Wei et al. 1998; Peng, Zhu et al. 1998; Zhou, Halanski et al. 
2000; Schulte, Czudnochowski et al. 2005).  Cyclin T1 in mouse cells has a point 
mutation (Y261R) within the Tat-TAR recognition motif, which disallows its interaction 
with Tat/TAR and has no effect on Tat transactivation.  Expression of human cyclin T1 
in mouse cells is capable of restoring the mouse cyclin T1 defect.  In summary, P-TEFb 
acts to phosphorylate the CTD of RNAPII in the early elongation complexes and converts 
RNAPII to be elongation-competent. 
 
2.4 Tat protein 
HIV-1 Tat stands for “trans-activator of transcription”.  It is encoded by two exons and 
has 85-101 amino acids depending on HIV-1 subtypes.  It is translated from multiply 
spliced transcripts that do not require Rev for their nuclear export.  Tat is structurally 
divided into five function domains: the N-terminal domain, the cysteine-rich domain, the 
core domain, the basic domain, and a C-terminal domain.  The N-terminal cysteine-rich 
core domain is also called the activation domain, where six cysteins are present and 
important for Tat /cynlin T1 interaction (Garber, Wei et al. 1998).  Another important 
domain for Tat function is the C-terminal arginine-rich domain; it is involved in Tat 
binding with TAR and also serves as a nuclear localization signal for Tat (Hauber, Miska 
et al. 1989; Siomi, Shida et al. 1990).   
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Tat is capable of transctivating the basal HIV-1 transcription (Robert A. Marciniak 1991; 
Qiang Zhou 1995).  In the absence of Tat, there are only a small number of short RNA 
transcripts produced, from which Tat protein is translated.  Newly translated Tat protein 
binds to cyclin T1 and mediates RNPAII phosphorylation, resulting in transcription of 
full- length HIV-1 mRNA (Amendt, Si et al. 1995; Suñé and Garc\'ia-Blanco 1995; Suñé, 
Goldstrohm et al. 2000; Montanuy, Torremocha et al. 2008). 
 
2.5 TAR 
TAR is 59 nucleotides (nt.) in length.  It forms an unusual secondary structure, which 
has a three-nucleotide bulge (nt. 23-25), and a six-nucleotide loop (nt. 30-35) and a 
central head nucleotide apical loop.  Tat binds to TAR at a trinucleotide bulge located 
near the apex of the TAR RNA stem-loop structure (Amendt, Si et al. 1995; Pereira, 
Bentley et al. 2000).  Specifically, Tat binds to nt.U23 in the bulge, and nt. A27, and 
nt.U38 and two phosphates between nt. A22, U23 and C24 serve to stabilize this binding.  
The cellular coactivaor of Tat, cyclinT1, binds to the central loop of TAR and creates a 
high-affinity Tat-TAR complex (Calnan, Tidor et al. 1991; Weeks and Crothers 1991). 
 
2.6 HIV-1 transcription initiation and elongation 
HIV-1 transcription is the limiting step for HIV-1 gene expression.  The first step of 
HIV-1 transcription is the formation of a large, multiprotein RNAPII holoenzyme, 
so-called pre-initiation complex (PIC) (Fig. 3).  The general transcription factors, 
including TFIIB, TFIID and TFIII, help to position the RNAPII at the starting site of 
transcription.  At this stage, the RNAPII CTD, which contains 52 repeats of 
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heptapeptied sequence (YSPTSPT), is not phosphorylated in either Ser2 or Ser5, and this 
form of CTD is called the CTDa.  Besides general transcription factors, other 
transcription enhancers like NF-kB and some histone acetyltransferases (HAT) are also 
recruited to increase the reinitiation at the LTR promoter (Sheridan, Mayall et al. 1997).  
It is also reported that Tat can bind to HAT such as CREB binding protein (CBP)/p300 or 
p300/CBP-associated factor (P/CAF) and affect the chromatin conformation of the LTR 
promoter (Benkirane, Chun et al. 1998). 
 
The next step of HIV-1 transcription is promoter clearance.  Transcription factor IIH 
(TFIIH) plays an important role in this step.  TFIIH contains DNA helicases and 
CDK-activating kinase CDK7 and is recruited to RNAPII CTDa by TFIIE.  Helicases 
can open the double strand DNA to allow it to be transcribed into RNA.  CDK7 
phosphorylates Ser5 of the RNAPII CTD and removes some transcription mediators 
bound to unphosphorylated CTD.  RNAPII is then released from pre-initiation complex 
and starts transcription (Zawel, Kumar et al. 1995).  In this stage of transcription 
initiation, Tat interacts with TFIIH and increases the CDK7 kinase activity.  It has been 
reported that a pseudosubstrate of CDK7 blocks Tat transactivation activity (Blau, Xiao et 
al. 1996; Cujec, Cho et al. 1997; Cujec, Okamoto et al. 1997). 
 
The transcription complex that is formed with TFIIH at the HIV-1 5’LTR becomes 
competent to initiate transcription but is less efficient in elongation.  The presence of 
NELF and DSIF in the initiation complex is mainly responsible for this inefficiency.  At 
this step, only short transcripts of about 60 nt are produced in the cytoplasm, indicating 
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that the integrated provirus is repressed by premature termination.  Also, a fraction of 
nuclear P-TEFb is inactive as it is bound to 7S RNA (Barboric, Kohoutek et al. 2005; 
Barboric, Yik et al. 2007; Li, Cooper et al. 2007; Sedore, Byers et al. 2007).  However, 
when Tat is translated from the short transcripts, it binds to cyclinT1 and recruits P-TEFb 
complex to the TAR RNA.  These interactions lead to phosphorylation of RNAP II Ser2 
by CDK9and as a result, increase the rigidity of the CTD and the affinity of human 
capping enzymes and act as a scaffold for splicing and polyadenylation process, which in 
turn increase transcription elongation, 5’-end capping, and histone methylation at the 
HIV-1 promoter (Zhou, Deng et al. 2003; Zhou, Deng et al. 2004).  This step is called 
transcription elongation.  P-TEFb is the key regulator for this step.  At later stages of 
elongation, Tat becomes associated with RNAP II rather than TAR RNA, indicating that 
the Tat:p-TEFb:TAR complex is disrupted during transcription (Gerber and Shilatifard 
2003; Shilatifard, Conaway et al. 2003; Sims, Belotserkovskaya et al. 2004). 
 
2.7 
As we described above, HIV-1 LTR utilizes both cellular factors and viral proteins to 
regulate HIV-1 LTR transcription.  HIV-1 LTR contains several binding site for host 
transcription factors, including NF-κB, nuclear factor of activated T-cells (NFAT), active 
protein-1 (AP1), sp1, these transcription factors function in HIV-1 basal transcription, 
and  enhance HIV-1 LTR-mediated gene expression(Gaynor 1992).  Other host 
transcriptional regulators, including HAT-1 and p300 serve to unwind chromatin 
nucleosome 1 located on HIV-1 LTR and thus greatly enhance viral gene transcription 
elongation.  Some cellular splicing factors also function in HIV-1 transcription.  
Host factors involved in HIV-1 transcription activation 
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Tat-splicing factor 1(SF1) and c-Ski-interacting protein (SKIP) are first identified as 
cellular splicing factors and later shown to be required for efficient transcriptional 
transactivation.  In particular, Tat-SF1 is a cofactor for stimulation of transcriptional 
elongation by HIV-1 Tat; SKIP associates with P-TEFb and enhances transcription 
elongation by HIV-1 Tat (Zhou and Sharp 1996; Fong and Zhou 2000; Kameoka, Duque 
et al. 2004; Vaness Bres Nathan Gomes and Jones 2005).  It is also reported that 
elongation factor ELL2, transcription factors/coactivators AF4/FMR 2 family member 4 
(AFF4), eleven-nineteen leukemia (ENL), are present in the Tat-P-TEFb complex.Tat 
and AFF4 function to bridge eleven-nineteen lysine-rich leukemia protein 2(ELL2) and 
P-TEFb together to form an elongation complex and significantly enhance HIV-1 
transcription (He, Liu et al. 2010). 
 
In the inactive P-TEFb complex, 7SK snRNP contains 7SK snRNA and CDK9 kinase 
inhibitor, HEXIM 1, and inhibits the P-TEFb kinase activity (Michels, Fraldi et al. 2004; 
Yik, Chen et al. 2004).  Host protein Yin Yang-1(YY1) has also been shown to repress 
HIV-1 gene expression via recruitment of histone deacetylase 1(Coull, Romerio et al. 
2000).  Interleukin-10 has been reported to down-regulate cyclin T1 expression through 
induction of proteasome-mediated proteolysis and to inhibit HIV-1 LTR-directed gene 
expression (Wang and Rice 2006).  Moreover, flavopitidol is shown to inhibit the 
P-TEFb kinase activity and block the HIV-1 transcription (Chao and Price 2001) 
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Figure 3. HIV-1 LTR transcription initiation and elongation  1. Pre-initiation 
complex formation: a pre-initiation complex is assembled at the LTR promoter.  It 
contains RNAPII, general transcription factors (GTF) and mediators that bind to 
unphosphorylated CTD.  Other transcription enhancers like NF-kB recruit histone 
acetyltransferases (HATs) to increase reinitiation at the LTR promoter.  2. Promoter 
clearance: TFIIH initiates promoter clearance.  CDK7 phosphorylates Ser5 of the 
RNAPII-CTD.  The transcription initiation starts.  3. RNAPII is only partially 
phosphorylated (RNAPIIa) and interacts with N-TEFb, which contains the DSIF and 
NELF.  The transcription process is blocked.  4. P-TEFb, containing CDK9 and cyclin 
T1, is recruited to the HIV-1 TAR by Tat.  CDK9 phosphosrylates Ser2 of the RNAPII 
and initiates HIV-1 transcription elongation step. 
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3. 
 
HIV-1 RNA SPLICING AND REGULATION 
3.1 Eukaryotic pre-mRNA splicing 
The pre-mRNA splicing is mediated by a large complex called spliceosome and requires 
small nuclear ribonucleoproteins (snRNPs) U1, U2, U5and U4/U6 and several 
non-snRNP splicing factors, such as U2-snRNP auxiliary factor (U2AF) and splicing 
factor 1 (SF1).  The major spliceosome splices out introns of pre-mRNA containing GU 
at the 5’ splice site and AG at the 3’ splice site (Staley and Guthrie 1998; Das, Zhou et al. 
2000; Nilsen 2002).  
During the splicing process, U1 snRNP first binds to GU sequence at the 5’ splice site 
while U2AF and SF1 associate with the 3’ splice site (Py-AG site).  The spliceosome at 
this stage is called E complex.  This is followed by association of U2snRNP with the 
branch point sequence (BPS) in the first ATP-dependent step of splicing, which is called 
A complex since ATP is hydrolyzed.  Then, U4-U5-U6 tri-snRNP joins A complex of the 
spliceosome.  The U5 snRNP binds the exons at the 5’ site, while U6 snRNP binds to U2 
snRNP.  This complex is called B complex.  Following a series of RNA-RNA and 
RNA-protein rearrangements, U1 and U4 snRNP are first released from the complex and 
a lariat structure is formed at this stage.  Subsequently, the 3’ site is cleaved and the 
exons are ligated with the second ATP hydrolysis.  Finally, the lariat structure 
debranches, the spliced RNA is released from the spliceosome (Nilsen 1996; Das, Zhou 
et al. 2000; Lallena, Chalmers et al. 2002).  
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3.2 HIV-1 mRNA alternative splicing 
Alternative splicing of HIV-1 mRNA precursors plays a critical role in regulating HIV-1 
gene expression (Fig. 4).  The alternative use of the 5’-and 3’-splice sites results in 
generation of approximately 40 spliced HIV-1mRNA species.  These RNA are divided 
into three classes: unspliced mRNA, singly spliced RNA and multiply spliced 
mRNA(Purcell and Martin 1993; Frankel and Young 1998).  Unspliced mRNA is 
necessary for expression of structural viral proteins or their precursors and also serves as 
genomic RNA.  Singly spliced mRNA encode the Env, Vpu,Vif and Vpr protein.  
Multiply spliced mRNA translate into Tat, Rev, and Nef (Felber, Hadzopoulou-Cladaras 
et al. 1989; Malim M.H. 1989).  HIV-1 mRNA splicing is a complex process.  It is 
highly regulated by three combined mechanisms: suboptimal splice sites; exonic and 
intronic cis-elements and trans-acting factors that regulate splicing by binding to 
cis-elements (O'Reilly, McNally et al. 1995; Caputi, Freund et al. 2004; Stoltzfus and 
Madsen 2006).  
 
3.3 Suboptimal splicing sites for HIV-1 
There are four splice donor sites (D1, D2, and D3andD4) and eight splice acceptor sites 
(A1, A2, A3, A4a, A4b, A4c, A5and A7) located throughout the full-length HIV-1 RNA 
genome (Fig. 4).  Among these splice sites, A3 is required for production of tat mRNA, 
A4a, b and c for production of rev and env mRNA, A5 for production of nef and env 
mRNA (Purcell and Martin 1993; Stoltzfus and Madsen 2006). 
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3.4 Exonic and intronic cis-acting elements 
Besides the splice sites, the efficiency of HIV-1 mRNA splicing is also regulated by both 
positive and negative cis-elements in HIV-1 RNA genome.  They either enhance or 
inhibit HIV-1 RNA splicing.  Some of these cis-sequences have been shown to interact 
with cellular factors. Positive cis-acting elements are known as exonic splicing enhancers 
(ESE), or intronic splicing enhancers (ISE), which increase the utilization of upstream 
3’splice site (ss) by binding to nuclear components that favor the association of 
spliceosomal components (Malim M.H. 1989; O'Reilly, McNally et al. 1995; Damier, 
Domenjoud et al. 1997; Frankel and Young 1998).  To the contrary, exonic splicing 
silencers (ESS) and intronic splicing silencers (ISS) decrease the utilization of the 
upstream 3’ ss and inhibit viral pre-mRNA splicing (Amendt, Si et al. 1995; Si, Amendt 
et al. 1997; Jacquenet, Méreau et al. 2001; Madsen and Stoltzfus 2005; Madsen and 
Stoltzfus 2006).  To date, four ESS, one ISS and four ESE have been identified within 
the viral genome (Amendt, Hesslein et al. 1994; Staffa and Cochrane 1995; Si, Amendt et 
al. 1997; Wentz, Moore et al. 1997; Si, Rauch et al. 1998).  ESE1 and ESSV are located 
downstream of A2 splice site and regulate vpr mRNA splicing (Frankel and Young 1998).   
ESSp, ESS2 and ESE2 are located in tat exon 2 and regulate A3 splice site (Jacquenet, 
Mereau et al. 2001; Hallay, Locker et al. 2006).  An ESE is also located downstream of 
A5 and used for the production of env mRNA (Caputi, Freund et al. 2004).  ESS3, ESE3, 
and ISS regulate A7 splice site and are important for all multiple spliced transcripts.  
22 
 
 
  
23 
 
 
 
 
 
 
Figure 4. HIV-1 mRNA alternative splicing and mRNA transcripts  The HIV-1 RNA 
genome contains four splice donor sites (D1, D2, D3, and D4) and eight splice acceptor 
sites (A1, A2, A3, A4a,A4b, A4c, A5, A7).  The alternative use of 5’-and 3’- splice sites 
results in generation of approximately 40 spliced mRNA species.  These RNA are 
divided into three classes: unspliced mRNA, singly spliced RNA and multiply spliced 
mRNA.  Unspliced mRNA is necessary for expression of structural viral proteins or 
their precursors and also serves as genome RNA.  Singly spliced mRNA encode the Env, 
Vpu, Vif and Vpr protein.  Multiply spliced mRNA translate into Tat, Rev, and Nef. 
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3.5 Trans-acting factors 
The regulatory cis-elements within the RNA genome often interact with trans-acting 
factors that function in the basal splicing machinery.  These factors are from either the 
arginie-serine (SR) protein family or the heterogeneous nuclear ribonucleoprotein 
(hnRNP) family (Table 1) (Zahler, Lane et al. 1992; Staley and Guthrie 1998; Caputi, 
Mayeda et al. 1999; Tange 2001; Caputi and Zahler 2002; Jacquenet, Decimo et al. 2005).  
Splicing component of 35KDa (SC35) and alternative splicing factor/splicing factor 2 
(ASF/SF2) of the SR proteins family mainly participate in the positive regulation of 
splicing by binding to ESE cis-elements, stabilizing the core splicing components to 
nearby splice sites and influencing the choice of splicing sites.  Specifically, SC35 
interacts with ESE2 cis-element and activates the 3’ss A3 splicing;  ASF/SF2 interacts 
with ESE3 cis-elements and activates the 3’ss A7 splicing (Fu 1993; Ismaili, Perez-Morga 
et al. 1999; Mayeda, Screaton et al. 1999; Ropers, Ayadi et al. 2004; Zahler, Damgaard et 
al. 2004).  In contrast, hnRNP proteins bind to ESS or ISS elements and are involved in 
negatively regulate mRNA splicing.  They have been shown to inhibit the usage of viral 
splice sites and to counteract the SR protein activity.  For example, hnRNP A1 protein 
interacts with ESS2 cis-element, competes with SC35 protein and inactivates upstream 
3’ss A3 splicing (Caputi, Mayeda et al. 1999; Jacquenet, Mereau et al. 2001) 
 
3.6 Splicing regulation of tat mRNA 
Tat is a critical regulatory protein for HIV-1 transcription elongation and production of 
full-length HIV-1 mRNA transcripts.  It also has an apoptotic activity on infected cells 
(Karn 1999; Hallay, Locker et al. 2006).  Thus, tat mRNA production is tightly 
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regulated.  All tat mRNA are spliced at 3’ss A3, the key control elements of site A3 are 
ESS2 and ESE2, both of which are located in tat exon 2 (Fig. 5).  ESS2 is located in the 
long stem-loop structure 3 (SLS3) and forms a stable complex with several hnRNP A1 
molecules via their C-terminal gly domain (Zahler, Damgaard et al. 2004).  ESS2 
contains the hnRNAP A1 recognition sequence UAG.  Mutations in each UAG triplets 
strongly reduce hnRNP A1 binding to ESS2.  ESE2 is in a close proximity to the ESS 
element, which binds to SR protein SC35 and SRp40, the two strong activators of site A3.  
As ESE2 is localized in a close proximity to ESS2, the SC35 binding site overlaps with 
the hnRNP A1 binding site.  hnRNP A1 binding to ESS2 masks the SC35 binding site 
ESE2 and blocks the U2AF association and subsequently inhibits splicing (Zahler, 
Damgaard et al. 2004; Hallay, Locker et al. 2006). 
 
4. 
 
MOLECULAR BIOLOGY AND FUNCTION OF TIP110 
4.1 
The bioinformatic analysis has revealed that the primary sequence of Tip110 protein 
contains three putative functional domains: half-a-tetratricopeptide repeat (HAT)-rich 
domain, RNA recognition motif (RRM) domain and nuclear localization signal (NLS) 
domain (Fig. 6). 
Predicted structure of Tip110 
 
4.1.1 HAT domain 
The N-terminal two-thirds of the Tip110 protein contains seven HAT motifs.  These 
HATs provide a structural unit of two antiparallel a-helices that assemble to form a 
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                Table 1. HIV-1 transacting splicing factors 
Acceptor sites Regulatory 
cis-elements 
Regulatory 
splicing factors  
Effects on HIV-1 
mRNA splicing  
A3 ESSp 
ESS2 
ESE2 
hn RNPH 
hn RNPA1 
SC35,SRp40 
- 
- 
+ 
A5 ESE GAR ASF/SF2, SRp40 + 
A7 ESS3 
 
ISS 
ESE3 
hn RNA1 
hn RNPE1/E2 
hn RNPA1 
ASF/SF2 
- 
- 
- 
+ 
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Figure 5. Regulation of HIV-1 3' splice site A3  (A). hnRNP A1 as a negative 
regulator.ESS2 silencer is located in the long stem-loop structure3 (SLS3) and forms a 
stable complex with several hnRNP A1 molecules.  This interaction blocks the 
interaction of SC35 to ESE2 and further blocks the recruitment of U2AF35 to the 3’ss of 
A3.  (B). SC35 as a positive regulator.  When ESS2 is mutated, hnRNP A1 proteins are 
replaced by SC35.  The role of SC35 at site A3 is to counteract hnRNP A1 binding to 
ESS2 and to recruit U2AF to the A3 site. 
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platform for protein-protein interaction. This domain is responsible for interaction of 
Tip110 with Tat (Liu, Li et al. 2002).  In addition, this domain is involved in Tip110 
interaction with a C-terminal region of the U4/U6 snRNP-specific 90 K protein and the 
reassembly of the U4/U6 snRNP (Bell, Schreiner et al. 2002).  
 
4.1.2 RRM domain 
Tip110 contains two RRM domains between aa740 and 874 in its C terminus.  These 
two RRM domains correspond to RRM 2 and 3 in yeast Prp24 (Gu, Shimba et al. 1998). 
An in vitro RNA binding assay shows that Tip110 is a nuclear RNA-binding protein(Bell, 
Schreiner et al. 2002), but there is no interaction between Tip110 and TAR domain (Liu, 
Li et al. 2002).  In addition, RRM deletion mutant retains the ability of Tip110 to 
increase the HIV-1 viral expression (Liu, Li et al. 2002).  
 
4.1.3  NLS domain 
The predominant nuclear speckle localization of Tip110 is dictated by NLS between aa 
600 and aa 670 of Tip110.  The deletion of the NLS domain does not interfere Tip110 
interaction with Tat protein, but completely relocates Tip110 expression from the nucleus 
to the cytoplasm (Liu, Li et al. 2002). 
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Figure 6. Functional domains of Tip110  Each functional domain is represented by a 
distinct color: HAT domain in red, NLS domain in pink, and RRM domain in orange.   
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4.2 Biological functions of Tip110 
 
4.2.1 Tumor rejection antigen 
Some genes encode tumor rejection antigens that can be recognized by cytotoxic T 
lymphocytes (CTL), some of these antigens are under clinical trials as peptide-based 
cancer immunotherapy.  However, only a few tumor rejection antigen genes have been 
identified so far.  In 1999, a human gene KIAA0156 was found to encode a shared 
tumor epitopes recognized by HLA-A24 restricted CTL in adenocarcinoma and 
squamous cell carcinoma (SCC) (Yang 1999).  This SCC antigen recognized by T cell 3 
(SART3) antigen is identical to Tip110 and possesses two epitopes that induce 
HLA-A24-restricted and tumor-specific CTL from peripheral blood mononuclear cells of 
the majority of cancer patients.  Moreover, the 140 kDa SART3 antigen protein is 
expressed in the nucleus of malignant cell lines and also in the majority of cancer tissues 
from various organs, including head and neck SCC, lung SCC, lung adenocarcinomas, 
melanomas, and fresh leukemia cells (Kawagoe 2000).  It is also expressed in the 
cytosol of all the proliferating cells including normal T cells and malignant cells but is 
undetectable in non-proliferating normal cells (Kawagoe 2000; Sasatomi 2002).  
Because some cancers are resistant to conventional chemotherapy or radiation therapy 
but responsive to various modes of immunotherapy, the SART3 antigen has been 
proposed as an appropriate target for treatment of certain cancers. 
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4.2.2 U4/U6 snRNP recycling 
During the splicing reaction, some spliceosome components need to be disassembled and 
reactivated before entering a new splicing cycle.  For example, U6 leaves the 
spliceosome after splicing in its singular form and has to reassociate with U4 snRNP to 
regenerate the U4/U6 snRNP.  During U6 snRNP recycling, Tip110 is demonstrated to 
be a recycling factor in the transition from the singular U6 snRNP to the U4/U6 snRNP in 
the mammalian cells (Bell, Schreiner et al. 2002).  
 
Tip110 is functionally related to yeast Prp24, which specifically binds to U6 and is 
required for U4/U6 annealing recycling (Gu, Shimba et al. 1998).  As the mammalian 
homolog of Prp24, Tip110 interacts with a C-terminal region of the U4/U6 
snRNP-specific 90 K protein through its HAT domain.  Also, Tip110 is present in U6 
and U4/U6 snRNPs but absent from both the U4/U5/U6 tri-snRNP and the spliceosome 
(Bell, Schreiner et al. 2002).  In vitro recycling assay has shown that Tip110 functions to 
bring U4 and U6 snRNAs together through both RNA-protein and protein-protein 
interaction with its RRM and HAT domains (Medenbach, Schreiner et al. 2004).  Tip110 
knockout results in thymus hypolasia, other organ-specific defects and ultimately 
embryonic death in zebrafish (Trede 2007).  Subsequent microarray expression profiling 
suggests that Tip110 knockout is compensated for by up-regulation of an extensive 
network of spliceosome components.  Tip110 also interacts with other cellular splicing 
factors.  Tip110 binds to RNA-binding protein with serine-rich domain 1 (RNPS1) 
through the physical association the S domain of RNPS1 and the C terminus of Tip110 
and promotes the proximal alternative 3’splicing of calcitonin-dihydrofolate reductase 
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pre-mRNA minigene (Kenji Harada.2001).  Our lab also has indentified Tip110 to 
interact with Y-box binding protein 1 (YB-1) protein and increase oncogene CD44 
alternative splicing (manuscript in preparation).  
 
4.2.3 HIV-1 viral gene expression 
Tip110 is an important cellular factor for HIV-1 gene expression and viral replication.  
Using the yeast two-hybrid assay, Tip110 is found to bind to Tat in vivo (Liu, Li et al. 
2002).  The N-terminal HAT-rich domain of Tip110 and the core domain of Tat are 
directly involved in the Tip110-Tat complex formation.  However, there is no interaction 
between Tip110 and TAR.  Tip110 is capable of transactivating the HIV-1 LTR promoter 
through direct interaction with Tat.  Tip110 expression is associated with increased the 
HIV-1 virus production while Tip110 knock down inhibits HIV-1 replication.  These 
results demonstrate that Tip110 plays an important role in HIV-1 virus replication and 
gene expression through interaction with Tat.  However, the underlying mechanisms 
were not understood and are the focus of the dissertation research.   
 
4.2.4 Androgen receptor (AR)-mediated transactivation 
AR is a nuclear receptor and is activated by binding of the androgenic hormones.  AR 
binds to DNA and mediates gene expression in different cellular processes, which are 
critical for the development and maintenance of the male sexual phenotype.  Like other 
nuclear receptors, AR is modular in structure and contains four functional domains: 
N-terminal regulatory domain, the DNA binding domain, hinge region, and the 
C-terminal ligand binding domain (LBD).  There are a number of cellular factors 
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regulating AR transactivation by direct interaction.  One common structure among these 
proteins is the presence of the LXXLL motif or nuclear receptor (NR) box.  This 
common NR box is sufficient for the interaction between co-regulator and the LBD of the 
AR. 
 
Tip110 protein has been shown to contain the NR domain between amino acids 118 and 
122, interact with AR, and negatively regulate AR transcription activation (Liu, Kim et al. 
2004).  AR transcription activation is recovered when Tip110 expression was 
down-regulated by anti-tip110 antisense RNA plasmid.  In addition, Tip110 
overexpression blocks expression of prostate surface antigen, an AR target gene.  
Tip110 prevents the complex formation between AR and AREs, which might account for 
the inhibition effects of Tip110 on AR transcriptional activation (Liu, Kim et al. 2004). 
 
5. 
The transcriptional activation of the HIV-1 LTR promoter is a key step in HIV-1 life cycle 
and requires coordinated action of viral protein Tat and cellular proteins.  These cellular 
factors function to either disassociate the negative inhibitor which blocks RNAPII 
phosphorylation from the promoter or recruit the elongation competent 
RNAPII-containing complexes to the promoter.  Using yeast two hybrid screening and 
HIV-1 Tat as bait, our group has first identified Tip110 protein to interact with Tat.  
Further studies have shown that Tip110 synergizes with Tat to transactivate HIV-1 LTR 
and HIV-1 gene expression and viral replication.  But the underlying molecular 
mechanisms were not understood.  In addition, evidence has accumulated to suggest that 
SUMMARY OF THE BACKGROUND AND OUR HYPOTHESIS 
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Tip110 interacts with splicing-related small nuclear RNA and other cellular splicing 
factors and enhances pre-mRNA splicing.  Therefore, the overall hypothesis of this 
dissertation is that Tip110 controls HIV-1 gene expression and replication through 
transcriptional activation of the HIV-1 LTR promoter and post-transcriptional splicing of 
HIV-1 genomic RNA.  We believe this study will add to our understanding of Tip110 
protein and yield new insights into the complex interaction network between HIV-1 and 
host cells. 
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METHODS AND MATERIALS 
 
MATERIALS 
 
Media and supplements 
Dulbecco’s modified eagle’s medium (DMEM) and Roswell Park Memorial Institute 
1640 (RPMI-1640) medium were purchased from Lonza (Walkersville, MD) 
Penicillin-streptomycin-glutamine (100X), Trypsin-EDTA (0.05%Trypsin, 0.53 mM 
EDTA) were purchased from GIBCO (Grand Island, NY).  Fetal bovine serum (FBS) 
was purchased from Hyaline (Logan, UT).  Ampicilin sodium salt (100 g/ml) and 
kanamycin sulfate (50 μg /ml) were purchased from United States Biological 
(Swampscott, MA).  Luria broth (LB) liquid medium contained 0.01 g/ml Bacto 
tryptone, 0.005 g/ml Bacto yeast extract, 0.005 g/ml NaCl, and 1 mM NaOH.  LB solid 
culture plates were prepared by adding 15 g Bacto agar to 1L LB liquid medium.  Super 
Optimal Broth with catabolite repression (SOC) contained: 0.02 g/ml of Bacto Tryptone, 
0.005 g/ml of Bacto yeast extract, 0.5 mg/ml NaCl, 10 mM MgCl2, and 10 mM 
MgSO4and 20 mM glucose.  
 
Antibodies 
Mouse anti-human RNAPII CTD antibodies (8WG16, H5, H14) (1:500) were from 
Covance (Greenwood, IN).  Rabbit anti-human CDK9 (1: 1000), goat anti-human cyclin 
T1 (1: 500), mouse anti-human hnRNP A1 (1:2000), rabbit anti-GFP (1:500), mouse 
anti-human PCNA (1:2000), mouse anti- GST (1:500), rabbit anti human c-Myc (1:1000),  
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mouse IgG, rabbit IgG, were from Santa Cruz Biotechnologies (Santa Cruz, CA).  
Donkey anti-rabbit IgG and sheep anti-mouse IgG horseradish peroxidase-conjugated 
antibody were from GE healthcare (Waukesha, WI).  Mouse anti-human ASF/SF2 
(1:2000) was from Invitrogen (Carlsbad, CA).  Mouse anti-human β-actin antibody was 
from Sigma (St. Louis, MO).  Mouse anti-human Tip110 1C4H6 (1:2000), rabbit 
polyclonal anti-human Tip110 serum was made in house.  
 
Reagents 
RNaseA, o-nitrophenylß-d-galactopyranoside(ONPG), 4’,6’-diamidino-2-phenylinole 
(DAPI)isopropyl-beta-D-thiogalactopyranoside(IPTG), phenylmethanesulphonylfluoride 
(PMSF) were from Sigma.  [Methyl-3H]-thymidne 5’ triphosphate was from 
PerkinElmer (Boston, MA).  [α-32P] dCTP (specific activity 800 Ci/mmol), and [α-32P] 
UTP (specific activity 800 Ci/mmol) were from MP Biomadicals (Solon, OH).  Poly-(A) 
x (dT) and random hexmers were purchased from Roche (Indianapolis, IN).  Restriction 
endonucleases were from New England Biolabs (Beverly, MA).  T4 DNA ligase with its 
10X reaction buffers were from USB (Cleveland, OH).  TRIZOL and Superscript III 
reverse transcriptases were from Invitrogen.  Bacto tryptone, Bacto yeast extract, Bacto 
peptone, Bacto were from Becton Dickinson (Sparks, MD).  RNase inhibitor and 
deoxynucleotide triphosphates (dNTPs-dATP, dCTP, dTTP, dGTP) were from Promega 
Corporation (Madison, WI).  Protease inhibitor cocktail set V, EDTA-Free and G418 
sulfate were from Calbiochem (LaJolla, CA).  Coomassie Blue was from Bio-Rad 
laboratories (Hercules, CA).  Tat protein was from AIDS Research and Reference 
Reagent Program.   
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Biotechnology systems 
The plasmid DNA purification kits, the firefly luciferase assay system, the Wizard SV 
Gel and PCR clean-up system and the Wizard DNA clean-up system for PCR products 
purification were from Promega Corporation (Madison, WI).  Bio-Rad Protein Assay 
was from Bio-Rad Laboratories.  Centricon 30 spin columns for protein concentration 
were from Millipore (Billerica, MA).  The Expand High Fidelity PCR system, Expand 
Long Template PCR system and the Titan One Tube RT-PCR System were from Roche.  
The TOPO TA cloning kit was from Invitrogen.  The MEGA Script T7 Kit was from 
Ambion (Austin, TX).  
 
METHODS 
 
Cells and cell cultures 
 
Cell lines 
Human embryonic kidney 293T cells were purchased from American Tissue Culture 
Collection (ATCC, Manassas, VA). Human glioblastoma-astrocytoma, epithelial-like cell 
lines U373 MAGI, human T-lymphoid CEM-GFP cells were obtained from NIH AIDS 
Research & Reference Reagent Program. 
 
Competent cells for cloning and recombinant protein production 
GC5 chemically competent E.coli for cloning were from GeneChoice (Frederick, MD) 
and BL21 E.coli for recombinant protein production were from Invitrogen. 
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Cell cultures 
293T cells and U373 MAGI cells were maintained in DMEM with 10% FBS, 100 
units/ml of penicillin at 37oC with 5% CO2.  CEM-GFP cells was maintained RPMI 1640 
with 10% FBS, 100 units/ml of penicillin, 500 μg /ml of G418 and incubated at 37oC 
with 5% CO2. 
 
Cell transfections and bacterial transformation 
 
Cell transfections 
Cell transfections were carried out by the standard calcium phosphate precipitation 
method. For 10-cm tissue culture plate, 2x106 cells were plated the day before 
transfection and incubated for about 24 hours to reach 70-90% cell confluency before 
transfection.  For transfection, a 500 μl mixture of 20 μg plasmid DNA and 0.24 M 
CaCl2 in a volume of 500 μl was added dropwise into 500 μl 2X HEPES-buffered saline 
(HBS) solution (50 mM Hepes, 10 mM KCl, 280 mM NaCl, 1.5 mM Na2HPO4, 12 mM 
glucose, pH 7.05-7.15).  The transfection mixture was then incubated on ice for 20 min 
and added dropwise into 293T cells.  After overnight incubation, medium was replaced 
with fresh DMEM medium. The cells were cultured for additional 24-48 hours before 
they were harvested for further analysis.  pcDNA3 was used to equalize the total DNA 
amount while pEGFP was co-transfected to ensure a comparable level of transfection 
efficiency among all transfections.  The number of cells and the amount of solutions and 
DNA were proportionally scaled down according to the surface area of the plates, if 
different sizes of cell culture vessels were used.  
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Bacterial transformation 
GC5 competent cells (25 μl) were incubated with plasmid DNA or ligation reaction 
(0.5-2 μl) on ice for 30 min.  The cells were heat-shock in a 42oC water bath for 45 sec, 
incubated on ice for 2 min, and added 300 μl SOC medium.  The transformation mixture 
was incubated at 37oC for 45 min on a shaker at 225 rpm.  Two hundred microliters of 
cultures were placed onto an LB agar plate.  The plate was incubated at 37oC overnight.  
 
Plasmids 
pTip110.His, pTip110.HA, Tip110 deletion mutants ∆RRM, ∆NLS, and ∆CT, pTat.Myc, 
pLTR-Luc plasmid were described previously (Liu, Li et al. 2002).  GST-CTD plasmid 
was a gift from Dr. David Price of University of Iowa.  pCMV-β-Gal, pcDNA3 and 
pCMV-HA were from Clontech ( Clontech, Mountain View, CA).  Tip110 ∆NT mutant 
was constructed using pTip110.His as the template and primers 5’-CCG AAT TCA CCA 
TGG CTG CCG TAG ATG TGG AG-3’ and 5’-CCC GCT CGA GTC AAT GAT GAT 
GAT GAT GAT GCT TTC TCA GAA ACA GCT TGG C-3’.  The PCR product was 
digested by EcoR I and Sac I and insert into pcDNA3.  pGST-hnRNP A1 was made by 
cloning hnRNP A1 gene from phnRNP A1-GFP (Guil, Long et al. 2006) with primer sets 
5’-CGG AAT TCC TCT AAG TCA GAG TCT CCT AAA GAG-3’ and 5’-CGG AAT 
TCC TCT AAG TCA GAG TCT CCT AAA GAG-3’.  The amplified product was then 
digested by EcoR I and Not I and subcloned into pGEX-4T3 for GST-hnRNP A1 protein 
preparation. 
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Plasmids pHS1-WT, pHS1-ESS4 mut and pHS2 plasmid were a generous gift from Dr. 
Martin Stoltzfus of University of Iowa.  pCMV-WT, or pCMV-ESS2-M minigenes were 
constructed by digesting pHS1-WT, pHS1-ESS2-M with Not I and Xho I, the inserts 
were and subcloned into pcDNA3.  pCMV-HS2-WT minigene was constructed using 
pHS2 as the template and primers 5’-GGG GTA CCG AAC AGT CAG ACT CAT 
CA-3’and 5’-CCG CTC GAG GGA TCC GTT CAC TAA TCG-3’.  The PCR product 
was digested by Kpn I and Xho I and inserted into pcDNA3.   
 
To prepare pT7-WT and pT7-ESS2-M plasmids, 60 bp DNA fragment containing ESS2 
or ESE2 was amplified with primers 5’-CCG GAA TTC AGA GGA GAG CAA GA-3’ 
and 5’-CTA GTC TAG AAG CTT GCT TCC AGG GCT CT- 3’ and pHS1-WT, 
pHS1-ESS2-M as templates.  Amplified products were then cut by EcoR I and Xba I 
and insert into pcDNA3 for further in vitro transcription.  
 
All recombinant plasmids were sequenced to ensure their sequences. 
 
Reporter gene assays 
 
β-galactosidase activity assay 
Cells were harvested in cold phosphate-buffered saline (PBS) and pelleted at 500 x g for 
5 min.  Then, cell pellet was resuspended in 50 μl cell lysis buffer from Promega and 
incubated on ice for 5 min and then centrifuged at maximum speed for 5 min.  The 
supernatant was collected and saved.  For β-galactosidase assay, 10 μl of cell extract 
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was mixed with 3 μl of 100X Mg2+ solution (0.1 M MgCl2, 4.5 M β-mercaptoethanol), 66 
μl of 1X ONPG (4 mg/ml ONPG in 0.1 M sodium phosphate, pH 7.5), and 201 μl of 
0.1M sodium phosphate (57.7 ml 1M Na2PO4and 42.3 ml of 1M NaH2PO4, pH 7.5) and 
the mixture was incubated at 37oC for 30 min.  Then, the optical density of the reaction 
containing the released o-nitrophenyl was measured at 405 nm in a microplate reader 
(Molecular Devices, Sunnyvale, CA) 
 
Luciferase activity assay 
β-galactosidase assay was used to normalize the transfection efficiency.  Then, cell 
extract (20 μl) was mixed with 80 μl of firefly or renilla luciferase substrate (Promega).  
The luciferase activity was determined with an Opticomp Luminometer (MGM 
Instruments, Hamden, CT) and expressed as relative luciferase units (RLU). 
 
Reverse transcriptase (RT) activity assay 
One milliliter of cell culture supernatant was centrifuged at 4oC for 1.5 hours at 14000 x 
g. Virus pellet was re-suspended in 10 μl of dissociation buffer (0.25% Triton-X-100, 20% 
glycerol, 0.05 M Tris-HCl. pH 7.5, 0.008 M DTT, 0.25 M KCl) followed by three cycles 
of freezing on dry ice and thawing on ice.  Then, 40 μl of 34 μl RT assay buffer (0.083 
M Tris-HCl pH7.5, 0.008 M DTT, 0,0125 mM MgCl2 and 0.083% Triton-X-100), 1 μl 3H 
dTTP and 5 μl poly (A) x (dt) was added to the 10 μl virus suspension.  The total 50 μl 
mixture was incubated at 37oC for 1hr and then spotted onto DE81 filters (Whatman, 
England).  After washing with 2 x SSC (0.3 M NaCl, 0.03 M sodium citrate, pH 7.0), 
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the radioactivity on each filer was counted in a Beckman LS6000IS scintillation counter, 
and virus titer was expressed as cpm per ml.  
 
Immunoblotting 
Two days after transfection, cells were first washed three times with ice-cold 
phosphate-buffered saline (PBS) and collected in cell lysis buffer (50 mM Tris.HCl pH 
8.0, 0.5% NP-40, 2 mM EDTA, 137 mM NaCl, 10% glycerol, 0.5% sodium deoxycholate, 
0.2% sodium azide, 0.004% sodium fluoride, 1x protease inhibitor cocktail, 1 mM 
sodium orthovanadate, pH 7.25).  After incubation on ice for 20 min, whole cell lysates 
were obtained by centrifugation at 15000 x g for 10 min.  The protein concentration was 
determined using a Bio-Rad DC protein assay Kit (Bio-Rad).  Cell lysates of an equal 
amount of protein were separated by 8%-12% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and then eletrotransfered to the HyBond-P membrane 
(Amersham, UK).  The protein on the membrane were probed with primary antibodies 
and appropriate peroxidase-labeled secondary antibody and visualized with an ECL 
system. 
 
The cytoplasmic fractionation was prepared by PARIS Kit (Ambion), according to the 
manufacturer’s instructions.  After wash with PBS, the cells were incubated with cell 
fractionation buffer on ice for 5 min.  The supernatant was collected by centrifugation at 
500 x g for 5 min and saved as the cytoplasmic fraction. 
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Immunoprecipitation 
Cells were harvested and washed with ice-cold PBS and lyzed in immunoprecipitation 
(IP) lysis buffer (50 mM Tris HCl pH7.5, 120 mM NaCl, 0.25% NP40, 4 mM sodium 
fluoride, 1 mM sodium orthovanadate, 0.2 mM EDTA, 0.2 mM EGTA, 10% glycerol, and 
1x protease inhibitor cocktail).  Following incubation on ice for 20 min, cell lysates 
were obtained by centrifugation at 15000 x g for 10 min.  Then, cell lysates of 500 µg 
protein was first pre-cleaned by 20 μl protein A agarose beads (Millipore) and then 
incubated with 1 μg antibody and 60μl protein A agarose beads rotating at 4oC overnight.  
The beads were recovered by centrifuge and then washed with IP washing buffer (50 mM 
Tris.HCl pH 8.0, 0.5% NP-40, 2 mM EDTA, 0.4 M NaCl, 10% glycerol) for four times.  
The beads were suspended in 40 μl of 4 x SDS-PAGE sample buffer and ready for 
SDS-PAGE and western blotting analysis. 
 
RNA isolation and RT-PCR-based splicing assay 
 
Total RNA was extracted from transfected 293T cells using Trizol reagent (Invitogen), 
according to the manufacturer’s instructions.  RNA was extracted with acid phenol for 
three times to prevent DNA amplification in subsequent PCR analysis.  For RT-PCR,  
0.2 μg RNA was used with a Titan One Tube RT-PCR System (Roche, Indianapolis, IN) 
on a PE Thermocycler 9700 (PE Applied Biosystem, Foster City, CA).  The primers to 
amplify minigene from pCMV-HS1-WT or pCMV-HS1-ESS4 were: Forward (T7): 
5’-TAA TAC GAC TCA CTA TAG GGC GA-3’; Reverse (Tat37): 5’-GGC TGC AGT 
TAA CAA ACT TGG CAA TGA AAG C-3’.  The primers for amplifying unspliced and 
spliced RNA from pCMV-HS2 were T7 and HS2-R: 5’-CCG CTC GAG GGA TCC GTT 
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CAC TAA TCG-3’.  The RT-PCR program was one cycle of 50oC for 30 min, thirty 
cycles of 94oC for 1 min, 60oC for 1 min, and 72oC for 30 sec and one cycle of 72oC for 5 
min.  The primers to amplify tat transcripts from pNL4-3 or pHIV-Rev- transfected cells 
were: TAR5: 5’-CCC GAA TTC GGG TTC CCT AGT TAG CCA GAGGAG CTC CCA 
GGC TCA GAT CT-3’; Tat21: 5’-GGC TGC AGT TAA GCA GTT TTA GGC TGA CTT 
C-3’; Tat5: 5’-GTC GGG ATC CTA ATG GAG CCA GTA GAT CCT; Tat3C: 5’-GTG 
ACG GAT CCT TAC TGC TTT GAT AGA GAA AC-3’ and the program was one cycle 
of 50oC for 30 min, thirty cycles of 94oC for 1 min, 50oC for 30 sec, 72oC for 45 sec and 
one cycle of 72oC for 5 min.  GAPDH was included in a RT-PCR as control with 
primers: 5’-GAA GGTGAA GGT CGG AGT-3’ and 5’-GAA GAT GGT GAT GGG ATT 
TC-3’.  
 
Multiplex RT-PCR 
293T cells were transfected with pNL4-3 as described above.  Two days post 
transfection, total cellular RNA was first isolated from the cells and further extracted with 
acid phenol for three times to prevent DNA amplification in subsequent PCR analysis.  
Three micrograms of RNA was reversed-transcribed at 50oC for 1 hr in a total volume of 
20 μl with 10 mM dNTPs (Promega), 200 U of RNase inhibitor (Promega), 500 ng of 
random hexamer (Roche) and 200 U of Superscript III reverse transcriptase (Invitrogen).  
Then, 1 μl of amplification products were used as template for multiplex PCR in a total 
reaction volume of 50 μl with 2.5 mM MgCl2, 0.2 mM dNTPs, 1 μM of each primer, and 
1 U of AmpliTag Gold (Applied Biosystems) with primers: BSS: 5’-GGC TTG CTG 
AAG CGC GCA CGG CAA GAG G-3’ and SJ 4.7, which spans sites D4 and D7 5’-TTG 
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GGA GGT GGG TTG CTT TGA TAG AG-3’.  The PCR program was 30 cycles of 
94oC for 30 s, 60oC for 1 min, and 72oC for 2 min and then denatured at 94oC for 5 min.  
Then, 5 μl of the above PCR products were labeled by addition of 1 μCi of 32P dCTP (800 
Ci/mmol, GE Healthcare) and additional 3 cycles of PCR.  The products were analyzed 
by electrophoresis on a 8 M urea 6% polyacrylamide gel, followed by drying of the gel 
for 1 hr using a vacuum gel dryer (Pharmacia biotech), and visualized by autoradiography.  
GAPDH was included as a RT-PCR control with the primers: 5’-GAA GGTGAA GGT 
CGG AGT-3’ and 5’-GAA GAT GGT GAT GGG ATT TC-3’. 
 
Recombinant protein expression and purification 
pGEX-4T3, pGST-CTD and pGST-hnRNP A1 were first transformed into E.coli BL21.  
The culture was allowed to grow to reach an OD600 of 0.6 and then added 0.5 mM 
isopropyl-β--thiogalactoside (IPTG) and continued to incubate at 37oCfor additional 3hr.  
The bacteria were collected by centrifugation at 6000 x g for 20 min and then suspended 
in TZ buffer (50 mM Tris-HCL pH 7.9, 12.5 mM MgCl2, 0.5 mM EDTA, 100 mM KCl, 
20% glyerol, 1 mM β-mercaptoethanol, 10 µM ZnCl2).  Then, cells were lysed in a 
French Press (Thermo electron corporation, Waltham, MA) at 1800 Psi.  Bacterial 
lysates were obtained by centrifugation at 20000 x g for 5 min.  To purify the protein, 
the lysate were mixed with 500 μl glutathione Sepharose 4B beads (GE Healthcare), and 
incubated at room temperature for 3 hr with constant rotation.  The bound proteins were 
washed for 3 times by PBS and proteins were eluted from the beads with 0.2 mM reduced 
glutathione.  The purity and the yield of the recombinant protein were verified by 
48 
 
SDS-PAGE, followed by coomassie staining (first stained in 10% acetic acid, 40% 
methanol, and 0.5% coomassie blue for 2 hr, and then distained in 10% acetic acid O/N).    
 
GST pull-down assay 
GST-CTD (6 μg) protein was first phosphorylated overnight at 30oC with 6 μl casein 
kinase I (New England Biolabs) and 1mM ATP with the phosphorylation buffer (New 
England Biolabs).  Meanwhile, 4 μg GST-Tip110 protein was digested with 1 μl 
thrombin at 30oC O/N to remove the GST tag.  Unphosphorylated or phosphorylated 
GST-CTD proteins were first immobilized onto 30 µl glutathione beads in at 4oC for 2 hr.  
Then,  the protein-bound beads were incubated with purified Tip110 protein in 500 µl 
GST pull down buffer (20mM Hepes pH 7.9, 150mM NaCl, 0.5mM EDTA, 10% glycerol, 
0.1% Triton X-100, 1mM DTT) at RT for 2 hr.  Subsequently, the protein bound beads 
were washed with PBS five times, the bound-protein were eluted from the beads by 4 x 
SDS-PAGE sample buffer.  The proteins were separated by SDS-PAGE and analyzed by 
immunoblotting.  
 
Chromatin immunoprecipitation (ChIP) assay 
Cells (5x107) were first cross-linked with 1% formaldehyde at RT for 20min; the 
cross-linking was terminated by adding glycine to a final concentration of 0.125M.  The 
cells were washed by PBS three times, the cell pellet was first resuspended in cell lysis 
buffer (85mMKCl, 0.5% NP40, 5mM HEPES, pH 8.0) and incubated on ice for 10 min.  
The nuclei were recovered by centrifugation at 3000 x g for 5 min and then resuspended 
in nuclear lysis buffer (10mM EDTA, 1%SDS, 50mM Tris-HCl, pH8.1).  The nuclei 
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were incubated on ice for additional 10 min; the supernatants were collected by 
centrifugation at 15000 x g for 10 min and saved as nuclear lysates. 
 
The nuclear lysates were then sonicated on ice with 10 pulses, each for 15 sec to generate 
chromatin DNA with an average size of 600 bp.  The sonicated lysates were diluted 
10-fold with a buffer (165mM NaCl, 0.01% SDS, 1.1% Triton X-100, 1.2mM EDTA, 
16.7 mM Tris-HCl, and pH 8.0) and pre-cleared with 30 µl protein A-sepharose beads.  
The lysates were first incubated with the indicated antibodies overnight, then added 60 µl 
protein A-sepharose beads and incubated for additional for 4 hr.  The immunocomplexes 
were washed twice with a low-salt buffer (150 mM NaCl, 0.1% SDS, 1% NP-40, 1 mM 
EDTA, 50 mM Tris-HCl), twice with a high-salt buffer (500 mM NaCl, 0.1% SDS, 1% 
NP-40, 1 mM EDTA, 50 mM Tris-HCl), twice with LiCl buffer (250 mM LiCl, 0.1% 
SDS, 1% NP-40, 1 mM EDTA, 50 mM Tris-HCl), and finally twice with TE buffer (0.25 
mM EDTA, 10 mM Tris-HCl).  The recovered beads were eluted with 120 µl elution 
buffer (1%SDS, 100 mM NaHCO3); the supernatants were collected and incubated at 
65oC overnight to reverse the formaldehyde cross-linking.  The DNA from the 
supernatants were isolated by phenol extraction, followed by ethanol precipitation and 
analyzed by PCR with primers spanning HIV-1 LTR promoter: 5’-CAT CCG GAG TAC 
TTC AAG AAC TGC-3’ and 5’-GGC TTA AGC AGT GGG TTC CCT AG-3’ or GAPDH: 
5’-GAA GGTGAA GGT CGGAGT-3’ and 5’-GAA GAT GGT GAT GGG ATT TC-3’.  
The PCR program was 35 cycles of 94oC for 1 min, 55oC for 1 min, and 72oC for 30 sec.  
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In vitro elongation assay 
Plasmid HIV-1dG-less is obtained from Dr.Carlos Sune of Instituto de Parasitologia y 
Biomedicina.  In vitro transcription assay was performed as described previously (Sune, 
Goldstrohm et al. 2000) with some minor modifications.  Briefly, recombinant Tat 
protein (100, 200 ng) and Tip110 protein (200, 400 ng) were mixed in buffer D (20 mM 
Hepes pH7.9, 0.1 M KCl, 20% glycerol, 0.2 mM EDTA, 0.5 mM DTT) and added to the 
nuclear extracts (3.5 μl/ reaction) (Promega) on ice.  Then, 200 ng linerlized DNA 
templates, unlabeled NTP, 4 U Rnase inhibitor and 400mM sodium citrate were added 
into total 25 μl transcripton reaction.  The mixture was incubated at 30oC for 30 min, 
followed by the treatment of 1μl DNase I to remove the DNA template.  RNA 
transcripts were recovered by phenol extraction and ethanol precipitation, and suspended 
in 10 μl ddH2O.  Two microliters of the RNA was used for RT-PCR analysis.  The 
primers to amplify the short G-less transcripts are 5’-GGG TCT CTC TGG TTA GAC 
CAG ATC TGA GCC TGG GAG CTC-3’ and 5’-AAA ACC AAA CCC TGC GCT CCA 
TCG CCA-3’.  The primers to amplify the long G-less transcripts are 5’-GCG AGG 
CAT AAA GTT GCG TGT G-3’ and 5’-AGG AGG GAG AGG TGA GGA GAG GAT-3’.  
The amounts of long and short transcripts were determined by RT-PCR followed by 
densitometric analysis of the PCR products; the ratio of the PCR products from long 
transcripts to those from the short transcripts was calculated and used as the elongation 
efficiency. 
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In vitro transcription 
The RNA probe for the gel shift assay was transcribed using a MEGA Script T7 system 
(Ambion) with plasmids pT7-WT and pT7-E2-M as templates.  The plasmids were first 
linerlized by Hind III, 1 μg of linerlized DNA was used for transcription.  Transcription 
was performed in an 25 μl system, containing 50 mM of ATP, CTP, GTP, 5mM UTP and 
2 μl [α-32P] UTP (800 Ci/mmol) at 37oC for 4 hours.  RNA was recovered by phenol 
extraction and ethanol precipitation.  The radioactive activity of the RNA sample was 
determined in a Beckman LS6000IC Scintillation counter (Fullerton, CA).   
 
Eletrophoretic mobility shift assay (EMSA) 
EMSA was performed with 10 pmol (about 20000 cpm) of 3’-end 32P labeled RNA probe. 
RNA was first incubated in 5 μl buffer D (0.2 mM EDTA, 0.2 M KCl, 0.5 mM DTT, 0.25 
mM PMSF, 20% glycerol, 20 mM HEPES-KOH pH 7.9) at 65oC for 5 min and allowed 
to cool down to the room temperature (RT) to eliminate its potential secondary structures.  
Then, 5 μl of buffer D containing indicated amounts of recombinant hnRNP A1, Tip110, 
or 1 μl nuclear extract was added to the RNA and then incubated for 15 min on ice for 
RNA-protein complex formation.  Competitor tRNAs (5 μg) was incubated in each 
reaction.  For supershift experiments, 1μl anti-hnRNP A1 4B10 (Santa Cruz) or 
anti-Tip110 1C4H6 was added at the end of the 15 min incubation, and the reaction was 
continued on ice for additional 15 min.  The reactions were then loaded onto a native 6% 
polyacrylamide (38:2 acrylamide/bis acrylamide) gel with 45 mM Tris-broate (pH 8.3) as 
the running buffer.  The gels were dried and then exposed to X-ray film.  
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Data acquisition and statistical analysis 
The expression levels of protein and mRNA expression levels were determined with a 
densitometer, calculated on the basis of the loading controls (β-actin for Western blotting 
and GAPDH for RT-PCR) and expressed as a relative value (Rel.) to the indicated control.  
In in vitro transcription assay, the levels of long and short transcripts were determined by 
RT-PCR, followed by densitometric analysis of the PCR products, the ratio of the PCR 
products from long transcripts to those from the short transcripts was calculated and used 
as the elongation efficiency.  In in vivo splicing assays, the levels of spliced transcripts 
and unspliced transcripts were determined by RT-PCR, followed by densitometric 
analysis of the RT-PCR products, the ratio of the PCR products from the spliced 
transcripts to those from unspliced transcripts was calculated and used to further calculate 
the splicing efficiency.  All values were expressed as means ± S.D.  Comparisons 
among groups were made using two-tailed Student’s t-test.  A p value of <0.05 was 
considered statistically significant (*), and p<0.01 highly significant (**). 
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RESULTS 
PART 1: Tip110 interacts with RNAPII and regulates Tat-mediated LTR 
transcription 
 
1.1 Tip110 enhances HIV-1 replication 
Our previous work has shown that Tip110 protein plays an important role in regulating 
HIV-1 gene expression (Liu, Li et al. 2002).  To confirm these findings, 293T cells were 
co-transfected with HIV-1 proviral DNA pNL4-3 and Tip110 expression plasmid 
pTip110.HA.  A pcDNA3-based GFP expression plasmid pc3.GFP was included as a 
control for Tip110 as well as a marker to monitor the transfection efficiency.  We 
harvested the cells and determined intracellular HIV-1 production by Western blotting 
against HIV-1 structural capsid protein p24.  Compared to the pc3.GFP control, ectopic 
Tip110 expression gave rise to higher level of p24 expression (Fig. 7A).In addition, cell 
culture supernatants were collected and the activities of HIV-1 reverse transcriptase (RT) 
was determined, which has also frequently been used as an indicator of HIV-1 titers in 
these supernatants.  Consistent with the intracellular HIV-1 p24 expression, Tip110 
expression increased HIV-1 titers by more than 6-fold over the GFP control (Fig. 7B).  
These results confirmed that Tip110 enhanced HIV-1 gene expression and production. 
 
1.2 Tip110 activates Tat-mediated LTR transcription 
Our previous studies have also shown that Tip110 interacts and synergizes with HIV-1 
Tat protein to transactivate HIV-1 LTR promoter (Liu, Li et al. 2002).  Thus, we 
determined if Tip110 would affect Tat-mediated transactivation activity.  293T cells 
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were transfected with HIV-1 LTR promoter driven luciferase (Luc) reporter gene and 
pTip110.HA, pTat.Myc, or both and performed the Luc reporter gene assay.  Vector 
backbone pcDNA3 was included in the transfection to equalize the total amounts of 
plasmid DNA transfected and pTKβ-Gal was included to normalize for variations in the 
transfection efficiency.  At 36h post-transfection, cells were harvested for the Luc 
expression assay.  As expected, Tat expression greatly increased the luciferase activity in 
a dose-dependent manner (Fig. 7C).  Tip110 over-expression slightly increased the 
luciferase activity (Fig. 7C), indicating that Tip110 may transactivate the HIV-1 LTR 
basal transcription.  When we transfected the cells with increasing amounts of 
pTip110.HA in the presence of a constant amount of pTat.Myc, the transactivation 
activity was greatly enhanced as demonstrated by the increase in luciferase activity from 
4.2x104 to 16 x104.  Taken together, these results confirmed that Tip110 itself was a 
weak transactivator of the HIV-1 LTR promoter but it synergized with Tat to enhance 
Tat-mediated transactivation activity.  
 
1.3 HIV-1 gene expression does not alter Tip110 expression 
Since Tip110 plays a role in viral gene expression and viral replication, we next 
determined if HIV-1 gene expression would affect Tip110 expression.  293T cells were 
transfected with increasing amount of pNL4-3. Western blotting was performed for 
intracellular HIV-1 p24, Tip110 and β-actin.  Tip110 expression showed little changes 
with increased expression level of p24 (Fig. 8), indicating thatHIV-1 gene expression 
does not alter endogenous Tip110 expression. 
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Figure 7. Tip110 enhancement HIV-1 viral replication by transactivating 
Tat-mediated LTR transcription  (A) 293T cells were transfected with indicated 
plasmids.  Whole cell lysates were obtained after 72h, 50μg of each whole cell lysate 
was analyzed by Western blotting for Tip110 and p24 expression. Also, Western blotting 
against β-actin was included as a loading control.  (B) The transfected cell culture 
supernatants (1 ml) was collected to determine the RT activity.  (C) 293T cells were 
transfected with 0.1μg of pLTR-luc plasmid, along with various amounts of pTat.myc (0, 
0.05, 0.1 μg), or pTip110.HA (0, 0.05, 0.1 μg), or 0.05μg of pTat.myc with increasing 
amounts of Tip110 (0, 0.025, 0.05 μg).  The vector backbone pcDNA3 was added to 
equalize the total amounts of DNA transfected and pTK-β-Gal was co-transfected to 
normalize the transfection efficiency.  Transfected cells were harvested after 72 h for the 
luciferase assay. * p<0.05, ** p<0.01.   
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Figure 8. Tip110 expression with HIV-1 gene expression  293T cells were transfected 
with pNL4-3 (0, 1, 2 and 4 µg).  Whole cell lysates were prepared after 72hr; lysates of 
50μg protein were analyzed by Western blotting for Tip110 and p24 expression.  
Western blotting against β-actin was included as a loading control.  
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1.4 Tip110 interacts with Tat 
To study the underlying mechanism of Tip110 function in LTR transactivation, we first 
determined whether Tip110 interacted with other transcription factors.  We first confirm 
the interaction between Tip110 and Tat.  293T cells were transfected with pTip110.HA, 
pTat.myc separately or Tip110.HA together with pTat.myc.  Also, pc3.GFP was added to 
equalize the total amount of DNA and to ensure a comparable level of transfection 
efficiency among transfections.  Western blotting analysis showed that both Tip110 and 
Tat expression were detected by anti-HA or anti-myc antibody (Fig. 9).  Subsequently, 
we performed immunoprecipitation of cell lysates for Tat followed by Western blotting 
for Tip110.  The results demonstrated that Tip110 was detected in the 
immunoprecipitation complex when Tat and Tip110 co-transfected (Fig. 9), which 
indicated that there was an interaction between Tip110 and Tat.  
 
1.5 Tip110 binds to the unphosphorylated (CTDa) but not the phosphorylated 
(CTDo) form of the RNAPII C-terminal domain (CTD) 
One of the essential events in HIV-1 LTR promoter transcriptional activation was 
phosphorylation of serine 2 and serine 5 of the RNA polymerase II C-terminal domain. 
Therefore, we investigated whether Tip110 directly interacted with RNAPII.  To this end, 
293T cells were transfected with pTip110.HA.  The immunoprecipitation was performed 
for unphosphorylated form of RNAPII (RNAPIIa), serine 2 phosphorylated RNAPII 
(RNAPIIo-ser2) or serine 5 phorphorylated RNAPII (RNAPIIo-ser5) by 8WG16, H5 and 
H14, respectively, followed by Western blotting for Tip110 (Fig. 10A).  The results 
showed that only the immunocomplex with 8WG16 had Tip110, which indicated Tip110 
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interacted with unphosphorylated form of RNAPII, but not with the phosphorylated form.  
To further characterize this interaction, immunoprecipitation was performed of the same 
cell lysate for Tip110 by anti-HA followed by Western blotting for the unphosphorylated 
or phosphorylated form of the RNAPII (Fig. 10B).  The results showed that only 
unphosphorylated RNAPII was detected in the immunoprecipitaion complex of Tip110, 
indicating that exogenousTip110 only associated with unphosphorylated RNAPII.  We 
further investigated whether endogenous Tip110 interacted with RNAPII by performing 
immunoprecipitation of 293T cell lysates with 8WG16, H14, and H5 followed by 
Western blotting against Tip110.  The result demonstrated that only the 8WG16 
immunocomplex contained Tip110 (Fig. 11A).  This interaction was further confirmed 
by detecting unphosphorylated RNAPII by 8WG16 in Tip110 immunoprecipitates (Fig. 
11B), indicating that endogenous Tip110 only interacted with the unphosphorylated form 
of RNAPII, but not its phosphorylated form. 
 
These Western blotting results showed much less phosphorylated RNAPII band than 
unphosphorylated RNAPII (Fig. 10 and 11).  This difference could result from different 
expression levels of these two forms of RNAPII or different efficiency of the antibodies 
for these two forms (H4, H5 and 8WG16) and could contribute to the finding that there is 
a complex formation between Tip110 and RNAPIIa.  Thus, in vitro GST pull-down 
assay was further performed to confirm Tip110 interaction with unphosphorylated 
RNAPII.  First, recombinant GST-CTDa protein was purified from E.coli and confirmed 
to contain RNAPII unphosphorylated C-terminal domain by Western blotting (Fig. 12A).  
Then, GST-CTDa was phosphorylated by casein kinase I in vitro.  Meanwhile,  
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Figure 9. The interaction between Tip110 and Tat  293T cells were transfected with 
pTip110.HA (lane2), pTat.myc (lane3), or both (lane 4), and harvest 48 h after 
transfection for whole cell lysates.  Mock transfection with pc3.GFP was also included 
(lane 1).  Forty micrograms of each whole cell lysate was analyzed by Western blotting 
to determine protein expression, and immnoprecipitation followed by Western blotting 
was used to determine Tip110 binding to Tat. 
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Figure 10. The interaction between exogenous Tip110 and RNAPII  293T cells were 
transfected with pTip110.HA or pc3.GFP.  After 3 days of incubation, we performed 
immunoprecipitation of cell lysates for unphosphorylated RNAPII (8WG16), 
phosphorylated RNAPII (H14 and H5), followed by Western blotting against Tip110 (A); 
Or immunoprecipitation against Tip110, followed by Western blotting for 
unphosphorylated RNAPII (8WG16) and phosphorylated RNAPII (H14 and H5) (B). 
  
66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
67 
 
 
 
 
 
 
 
Figure 11. The interaction between endogenous Tip110 and RNAPII             
(A) Immunoprecipitation was first performed on 293T cell lysates (500 μg) for the serine 
2 or serine 5 phosphorylated RNAPII, or unphosphorylated RNAPII.  These 
immunoprecipitates were then analyzed by Western blotting for Tip110 (upper panel).  
Western blotting for 8WG16, H5, and H14 were also performed against their own 
immunoprecipitates as the control (lower panel).  (B) Immunoprecipitation was 
performed with anti-Tip110 antibody, followed by Western blotting for 8WG16, H5 and 
H14 (upper panel) or for Tip110 protein as the control (lower panel).  
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Figure 12. The interaction between Tip110 with RNAPII-CTD in vitro 
(A) GST-CTDa protein was purified from E.coli, and further phosphorylated by casein 
kinase I.  To check the phosphorylation efficiency, Western blotting was performed 
against 8WG16, H14 and H5.  GST was added as a loading control.  (B) Tip110 
protein was prepared by thrombin cleavage of GST-Tip110 and then purified by 
glutathione beads to remove GST protein.  Western blotting analysis was performed for 
Tip110 and GST to ensure correct expression of Tip110 and Tip110-GST fusion protein 
and complete GST removal from Tip110 protein.  (C) Unphosphorylated or 
phosphorylated GST-CTD and GST protein were immobilized with 50 μl glutathione 
beads and incubated with purified Tip110 protein for 2 hours.  After washing, the 
protein from the pellet fraction (lanes 2-4) and supernatant fraction (lanes 5-7) were 
detected by Western blotting for Tip110; Purified Tip110 protein was included as the 
positive control to indicate the correct protein size (lane 1). The membrane was stripped 
and re-probed with anti-GST to ensure a comparable amount of GST-CTDa and 
GST-CTDo. 
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recombinant Tip110 was prepared by removing the GST tag from GST-Tip110 with 
thrombin (Fig. 12B).  Then, glutathione beads coated with purified GST, GST-CTDa or 
GST-CTDo were incubated with recombinant Tip110 protein.  Bound protein that 
remained on the beads as well as the protein from the supernatant fraction was analyzed 
by SDS-PAGE gel followed by Western blotting with Tip110 monoclonal antibody.  The 
results showed direct binding of Tip110 to unphosphorylated CTD (Fig. 12C, lane 3), but 
not GST protein (Fig. 12C, lane 2) or phosphorylated CTD (Fig. 12C, lane 4).  Taken 
together, this data demonstrated that Tip110 associated with unphosphorylated RNAPII 
CTD, but not with phosphorylated form of RNAPII at either serine 2 or serine 5. 
 
1.6 HAT domain is important for Tip110 interaction with RNAPIIa 
To determine which functional domains of Tip110 interacts with unphosphorylated 
RNAPII, we took advantage of a series of Tip110 mutants which contained RRM domain, 
C-terminal domain, NLS domain or HAT domain deletions (Fig. 13A).  Due to 
differences in antibody epitopes, the Tip110 mutants divided into two groups for Western 
blotting detection:∆RRM, ∆NLS, and ∆CT mutants were detected by anti-156 serum, and 
∆NT was detected by Tip110 monoclonal antibody.  293T cells were first transfected 
with each of Tip110 mutants and their expression was confirmed by Western blotting (Fig. 
13B & 13C).  Then, immunopreciptations with 8WG16 was performed followed by 
Western blotting for Tip110.  The mutants lacking the NLS domain, RRM domain or 
C-terminal domain bound to unphosphorylated RNAPII as efficiently as the full length 
protein (Fig. 13B).  But deletion of the HAT domain abolished the Tip110-RNAPII  
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Figure 13. The requirement of HAT domain for Tip110 binding to RNAPII 
(A) Schematic of wild-type Tip110 and its mutants.  (B) 293T cells were transfected 
with indicated Tip110 mutants or wild type Tip110.  The upper two panels were Western 
blotting with anti-156 serum (Tip110) or 8WG16 (CTDa) after immunoprecipitation with 
8WG16 antibody.  The lower two panels were Western blotting of input whole cell 
lysates for expression of Tip110 mutants and CTDa.  (C) 293T cells were transfected 
with ∆NT or wild-type Tip110 and analyzed for protein expression of Tip110 or CTDa 
(right two panels).  The interaction of ∆NT or Tip110 with unphosphorylated CTD was 
detected by immunoprecipitation using 8WG16 followed by Western blotting for Tip110 
(left two panels). 
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complex formation (Fig. 13C), indicating that HAT domain of Tip110 was directly 
involved in Tip110-RNAPII interaction. 
 
1.7 Tip110 does not interact with P-TEFb 
Since Tip110 and P-TEFb were co-localized in nuclear speckle structure, we further 
determined if Tip110 interacted with CDK9 or cyclin T1 by immunoprecipitation and 
Western blotting.  First, we examined whether endogenous Tip110 was part of the 
P-TEFb and found that neither endogenous cyclin T1 nor CDK9 was detected in 
anti-Tip110 immunoprecipitates (Fig. 14A).  Similarly, no Tip110 protein in either 
anti-CDK9 or anti-cyclin T1 immunoprecipitates was detected (Fig. 14B).   
 
To eliminate the possibility that endogenous Tip110 expression level was too low to 
detect the interaction, exogenous Tip110-expressing 293T cells were used for IP/WB.  
Immunoprecipitation followed by Western blotting demonstrated no Tip110/CDK9 or 
Tip110/cyclin T1 complex formation (Fig. 15A & 15B).  CDK9 and cyclin T1 antibody 
worked, as they were capable of immunoprecipitating each other as a complex (Fig. 14B) 
(Wei, Garber et al. 1998).  Therefore, we concluded that Tip110 did not associate with 
CDK9 or cyclin T1. 
 
1.8 Tip110 interaction with Tat recruits more P-TEFb to the transcription complex 
We next determined if Tip110 interaction with Tat would recruit more P-TEFb to the 
HIV-1 transcription complex.  293T cells were first transfected with pLTR-Luc, and 
pTat.myc, pTip110.HA, or both.  At 48hr post transfection, Western blotting was  
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Figure 14. No interaction between endogenous Tip110 and p-TEFb 
(A) Immunoprecipitation was performed for endogenous Tip110 or mouse IgG followed 
by Western blotting for cyclin T1 or CDK9 (upper panel).  Western blotting for Tip110 
of Tip110 immunoprecipitates was also performed as the positive control (lower panel).  
(B) Immunoprecipitation was performed for cyclin T1 or CDK9 separately followed by 
Western blotting for Tip110 (upper panel).  Western blotting for cyclin T1 or CDK9 of 
cyclin T1 or CDK9 immunoprecipitates was performed as the control (lower panel).  
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Figure 15. No interaction between exogenous Tip110 and P-TEFb  293T cells were 
transfected with pTip110.HA, or pc3.GFP.  The whole cell lysates were obtained after 
72h.  (A) Western blotting for Tip110 was performed for cell lysates (lanes 1, 2) and 
anti-CDK9 (lanes 3, 4) or anti-cyclin T1 (lanes 5, 6) immunoprecipitates.  (B) 
Immunoprecipitation was performed of cell extracts for Tip110 (α-HA) (lanes 3, 4) or 
CDK9 (lanes 5, 6) and followed by Western blotting for cyclin T1.Immunoprecipitation 
was performed for Tip110 (α-HA) (lanes 3, 4) or cyclin T1(lanes 5, 6) and then Western 
blotting for CDK9. 
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Figure 16.The recruitment of P-TEFb to the transcription complex by Tip110 and 
Tat  (A) 293T cells were transfected with pLTR-luc (lane 2), pTip110.HA with 
pLTR-luc (lane 3), pTat.myc with pLTR-luc (lane 4), or pLTR-luc with pTip110.HAand 
pTat.myc (lane 5).  Mock transfection with pcDNA3 (lane 1) was also included as a 
control.  The expression of Tip110, Tat, cyclin T1, CDK9 and β-actin were detected by 
Western blotting.  (B) The binding of cyclin T1 with Tat was determined by 
immunoprecipitation with c-myc (Tat) followed by Western blotting for cyclin T1, or 
anti-myc as the control (upper two lanes).  The interaction of CDK9 with RNAPII was 
determined by Western blotting for CDK9 of 8WG16 immunoprecipitates.  Western 
blotting for 8WG16 was also performed for 8WG16 immunoprecipitates as the control 
(lower two lanes). 
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performed to detect Tip110, Tat, CDK9 and cyclin T1 expression, demonstrating neither 
Tip110 nor Tat expression altered CDK9 and cyclin T1 expression (Fig. 16A).  Then, we 
performed immunoprecipitation for Tat and Western blotting for cyclin T1.  As we 
expected, cyclin T1 was detected in Tat immunoprecipitates when Tat overexpressed 
(Fig. 16B, upper two panels).  But Tip110 increased cyclin T1 in Tat 
immunoprecipitates by more than 2 fold.  Tip110 also increased unphosphorylated 
RNAPII-associated CDK9by about 1.4 fold, as shown by immunoprecipitation against 
8WG16 followed by Western blotting for CDK9 (Fig. 16B, bottom two panels).  These 
results indicated that Tip110 interaction with Tat recruited more P-TEFb to the 
transcriptional complex. 
 
1.9 Tip110 and Tat enhance RNAPII phosphorylation 
The most critical step during HIV-1 LTR promoter transactivation is the phosphorylation 
of RNAPII (Zhu, Pe'ery et al. 1997; Kim, Bourgeois et al. 2006).  CDK7 phosphorylates 
serine 5 of RNAPII for the transcription initiation; whileCDK9 phosphorylates serine 2 
for transcription elongation (Wei, Garber et al. 1998; Chen and Zhou 1999).  Since 
Tip110 could recruit more P-TEFb to the transcription complex, we next determined the 
effects of Tip110 and Tat expression on RNAPII phosphorylation.  We transfected 293T 
cells with increasing amounts of pTip110.HA, pTat.Myc, or a constant amount of 
pTat.Myc and increasing amounts of pTip110.HA.  After 48 hours, Western blotting 
analysis was performed against unphosphorylated form of RNAPII (RNAPIIa), serine 2 
phosphorylated RNAPII (RNAPIIo-ser2) or serine 5 phorphorylated RNAPII 
(RNAPIIo-ser5) by 8WG16, H5 and H14, respectively (Fig. 17A).  When Tip110 was  
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Figure 17. Enhancement of RNAPII CTD phosphorylation by Tip110 and Tat 
(A) 293T cells were transfected with increasing amounts of pTip110.HA (0, 0.5, 1.0, 4.0 
μg), increasing amount of pTat.myc (0, 0.5, 1.0, 4.0 μg), or a constant amount of 
pTat.myc (0.5 μg) with increasing amounts of pTip110.HA (0, 0.5, 1.0, 4.0 μg). pcDNA3 
was added to equalize the total amounts of DNA transfected.  Cells were cultured for 
72h and then harvested for whole cell lysates. Samples were first analyzed by Western 
blotting for Tip110 or Tat.  Then, unphosphorylated RNAPII (IIa), and serine2 (IIo-ser2) 
and serine5 (IIo-ser5) phosphorylated RNAPII levels were determined by antibody 
8WG16, H5, H14, respectively.  (B) Quantification of Western blot densitometry data 
from three independent experiments.  
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Figure 18
293T cells were transfected with increasing amounts of pTip110.HA (0, 0.5, 1.0, 4.0 μg), 
increasing amount of pTat.myc (0, 0.5, 1.0, 4.0 μg), or a constant amount of pTat.myc 
(0.5 μg) with increasing amounts of pTip110.HA (0, 0.5, 1.0, 4.0 μg).  pcDNA3 was 
added to equalize the total amounts of DNA transfected.  Cells were harvested after 72 
hours and analyzed by Western blotting against anti-CDK7, anti-cyclin H, anti-CDK9, 
anti-cyclin T1 and anti-β-action as the loading control.  
. TFIIH and P-TEFb expression inTip110 -and Tat-expressing cells 
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expressed, both RNAPIIo-ser2 andRNAPIIo-ser5 were increased by 2 fold and RNAPIIa 
was decreased (Fig. 17B, left panel).  In Tat expressing cells, RNAPIIa was slightly 
reduced, RNAPIIo-ser5 showed little change, but RNAPIIo-ser2 was increased by 1.5 
fold (Fig. 17B, middle panel).  When Tat and Tip110 were co-expressed, RNAPIIo-ser2 
and RNAPIIo-ser5 both increased by 3 fold, with RNAPIIa was decreased by 0.3 fold 
(Fig. 17B, right panel).  These results indicated that Tip110 together with Tat could 
enhance the phosphorylation of RNAPII at both serine 2 and serine 5, which may 
accounted for the Tip110 function in transcription activation.  
 
1.10 Neither Tip110 nor Tat protein alters P-TEFb or TFIIH expression level 
P-TEFb and TFIIH phosphorylate RNAPII (Wei, Garber et al. 1998; Chen and Zhou 
1999). Thus, we further investigated whether increased RNAPIIo was due to the 
up-regulation of P-TEFb or TFIIH expression by Tip110 and Tat expression.  To this end, 
293T cells were transfected with increasing amounts of pTip110.HA, pTat.Myc, or a 
constant amount of pTat.Myc and increasing amounts of pTip110.HA.  Then, Western 
blotting was performed against CDK9, cyclin T1, CDK7 and cyclin H (Fig. 18).  The 
results demonstrated that Tip110, Tat or both did not significantly alter expression of 
these four proteins, indicating that increased RNAPII phosphorylation by Tip110 or Tat 
was not due to any changes in the expression levels of P-TEFb or TFIIH components.  
 
1.11 Tip110 is detected at the HIV-1 LTR core promoter 
To determine whether Tip110 was recruited to the HIV-1 LTR promoter in vivo, ChIP 
experiments were carried out in exogenous Tip110-expressing 293T cells, or with 
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endogenous Tip110 in U373-MAGI and CEM-GFP cells.  The HIV-1 LTR core 
promoter and the primers for the ChIP assay were showed in Fig. 19A.  For ChIP assay 
with exogenous Tip110, 293T were transfected cells with pNL4-3 proviral plasmid and 
pTip110.His plasmid, and the overexpression of Tip110 was confirmed after 3 days (Fig. 
19B, lanes 1, 2).  Chromatin from cells was isolated, immunoprecipitated with 
anti-mouse IgG, 8WG16 or anti-His antibody followed by PCR to amplify the HIV-1 
LTR core promoter region.  As a control for ChIP experiment, we amplified LTR 
promoter in the RNAPII immunocomplex (Fig. 19C, lane 4) and LTR promoter could be 
also amplified in the Tip110 immunocomplex, indicating Tip110 was present at the HIV-1 
LTR promoter in vivo (Fig. 19C, lane 5).  As negative a control, mouse IgG was not 
detected at the LTR promoter (Fig. 19C, lane 3) and neither RNAPII nor Tip110 were 
detected on GAPDH coding region (Fig. 19C, lower panel), which served as a PCR 
control.  Thus, we concluded that exogenous Tip110 was recruited to the transient LTR 
promoter.  To determine if endogenous Tip110 was present in the integrated HIV-1 
promoter, we took advantage of CEM-GFP cells that have an integrated HIV-1 LTR 
promoter-driven GFP transgene cassette and U373MAGI cells that have an integrated 
HIV-1 LTR promoter-driven Lac Z transgene cassette.  Western blotting was first 
performed to confirm expression of endogenous Tip110 in these two cells (Fig. 19B, lane 
3, 4).  Chromatin was isolated from these cells, immunoprecipitated with mouse IgG, 
8WG16 or Tip110 monoclonal antibody, and subjected to PCR for the HIV-1 LTR core 
regions or GAPDH.  The result showed that positive control RNAPII and endogenous  
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Figure 19. The complex formation between Tip110 and HIV-1 LTR core promoter 
(A) Schematic of the LTR core promoter and expected primer sites for LTR PCR 
amplification.  (B) Western blot analysis for exogenous Tip110 expression in 293T cells 
(lane 1), and endogenous Tip110 expression in 293T (lane 2), U373MAGI (lane 3), and 
CEM-GFP cells (lane 4).  (C) 293T cells were transfected with the indicated plasmid.  
At 72h post-transfection, chromatin from these cells was cross-linked, sheared, and 
immunoprecipitated with the indicated antibodies.  After reversing the cross-linking,  
DNA was purified and analyzed by PCR with primer sets specific for the HIV-1 LTR 
promoter region (upper two panel), with the GAPDH coding region (lower two panels) 
included as the negative control.  (D) ChIP experiment was performed as described 
above with endogenous Tip110 expressed in U373MAGI cells (upper two panels) and 
CEM-GFP cells (lower two panels). 
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Tip110 were detected at the LTR promoter in both CEM-GFP and U373- MAGI cells 
(Fig. 19D, lane 4, 5), indicating Tip110 was detected at the HIV-1 LTR core promoter in 
vivo. 
 
1.12 Tip110 recruits more P-TEFb to the HIV-1 LTR promoter 
We then evaluated the recruitment of the Tat-induced elongation complex to the LTR core 
promoter in the presence of Tip110.  293T cells were first transfected with pLTR-Luc, 
and pTip110.HA, pTat.myc, or both.  Then, ChIP assay was performed with 
immunoprecipitation against Tat, Tip110, cyclin T1, CDK9, unphosphorylated RNAPII, 
and serine 2 or serine 5 phosphorylated RNAPII followed by PCR amplifying HIV-1 LTR 
core region (Fig. 20A).  As positive controls, both Tat and Tip110 protein could be 
detected at the LTR core region.  No CDK9 or cyclin T1 was detected at the LTR 
promoter in the absence of Tat; but with Tip110 over-expression, there are significant 
increases in the levels of cyclin T1 and CDK9 recruited to the LTR promoter.  
Meanwhile, serine 2 RNAPII phosphorylation was only observed in the LTR promoter 
with Tat expression and showed about 2 folds increase in the presence of Tip110, while 
serine 5 RNAPII phosphorylation could be detected without Tat expression and showed 
little change in the presence of Tip110 and Tat.  As we expected, neither P-TEFb nor 
RNAPII could be detected at the LTR promoter when immunoprecipitation was 
performed with mouse IgG control.  As a negative control, PCR for GAPDH coding 
region showed low level of RNAPII detected on the GAPDH region (Fig. 20B).  These 
data together suggested that the Tip110 interaction with Tat was capable of recruiting 
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increased P-TEFb to the HIV-1 LTR promoter, and further enhanced RNAPII serine 2 
phosphorylation at the LTR core promoter. 
 
1.13 Tip110 and Tat increase the LTR transcription elongation 
To determine if Tip110 interaction with Tat had direct effects on HIV-1 transcription 
elongation, we performed in vitro G-less transcription/elongation assay with some 
modifications.  The template pHIV-dG-less contains two G-free cassettes downstream 
from the HIV-1 LTR promoter, its short (promoter-proximal) and long (promoter-distal) 
transcripts are RnaseT1 resistant.  This template has been used to determine 
transcription initiation and elongation respectively (Fig. 21A) (Montanuy, Torremocha et 
al. 2008).  Following in vitro transcription of the G-less DNA template, we treated the 
reaction with DNase I and then performed RT-PCR to determine the relative levels of 
short and long G-less transcripts using two pairs of primers that were specific for each of 
those two transcripts.  These two pairs of primers were expected to give rise to about 
300bp and 520 bp PCR products, respectively.  Recombinant Tat or Tip110 proteins 
were included in the reaction.  As expected, Tat increased the long transcript level but 
had little effect on the short transcript level (Fig. 21B).  Compared to Tat, Tip110 also 
slightly increased the long transcript level and had little effects on the short transcript 
level.  Compared to Tat or Tip110, the presence of both proteins further increased the 
long transcript level and had no effect on the short transcript level.  These results 
indicated that Tip110 interaction with Tat increased the elongation efficiency of RNAPII 
complexes formed on the LTR promoter. 
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To further ascertain the significance of Tip110 protein in Tat-mediated LTR transcription 
elongation, we determined if depletion of endogenous Tip110 would affect Tat-activated 
LTR transcription.  To achieve this, we first immunodepleted Tip110 from nuclear 
extract by anti-Tip110 and saved the supernatant fractions from the depleted extracts.  
Immunodepletion with IgG was included as a control.  Western blotting confirmed that 
immunodepletion with anti-Tip110 antibody resulted in more than 70% Tip110 from the 
Nuclear extract (Fig. 22A).  Then, the in vitro G-less assay was carried out with Tip110- 
depleted nuclear extract.  Tip110 depletion reduced the HIV-1 LTR derived long 
transcripts but had minimal effect on short transcripts, indicating that Tip110 is critical 
for RNAPII transcription elongation (Fig. 22B, lane 1, 2).  However, when Tip110 was 
added back to the Tip110-depleted nuclear extract, the transcription elongation level was 
not recovered.  The inability of recombinant Tip110 to restore the transcription 
elongation is likely due to the depletion of other transcription factors associated with 
Tip110 from the nuclear extract, such as RNAPII (Fig. 22B, lane 3).   
 
To overcome this problem, we decided to knock down endogenous Tip110 by 
Tip110-specific shRNA and performed the in vivo G-less assay in Tat-expressing cells.  
We transfected pHIV-dG-less plasmid with pTat.myc into 293T cells on day 0, 4 or day 7 
following pshTip110 transfection and harvested cells at day 7 or day 10 for Western 
blotting or RNA isolation and RT-PCR.  The pshTip110 backbone vector pSIREN was 
included as a control.  Western blotting demonstrated that endogenous Tip110 protein 
expression was considerably knocked down by pshTip110in day 7 after transfection and 
slightly recovered at day 10 (Fig. 22C).  In contrast, Tip110 expression showed little 
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changes in pSIREN transfection.  In parallel with Tip110 expression, RT-PCR analysis 
showed that Tat-induced long transcripts synthesized from LTR decreased at day 7 and 
began to increase at day 10 (Fig. 22D).  pshTip110 transfection showed no changes in 
short transcripts.  pSIREN had no changes in either long or short transcripts.  Taken 
together, these results demonstrated a specific role of Tip110 in RNAPII elongation on 
the LTR promoter. 
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Figure 20. The recruitment of P-TEFb to the LTR core promoter by Tip110 and Tat  
293T cells were transfected with the indicated plasmids.  At 72h post-transfection, 
chromatin from these cells was cross-linked, sheared, and immunoprecipitated with the 
indicated antibodies.  After reverse cross-linking and phenol extraction, the purified 
DNA was amplified with primer sets for the HIV-1 LTR promoter (A) or GAPDH primer 
(B) as control.  (C) PCR products for LTR core promoter were quantitated by 
densitometry and expressed as fold increase over the input control.  The data were 
representative of three independent experiments. *: p<0.05, **: p<0.01. 
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Figure 21. Direct effects in HIV-1 transcription elongation by Tip110 and Tat 
 
(A) Schematic of HIV-1 LTR double G-less cassette template used in the experiment. The 
transcript synthesized by this template contains two G-less cassettes.  Upstream G-less 
cassette is located proximal to the promoter and used to measure transcription initiation, 
the downstream cassette is used to measure transcription elongation.  The primer 
locations to amplify the short and long transcripts were shown.  (B) The in vitro 
transcription/elongation assay was performed with HIVdG-less plasmid and 0, 100, 200 
ng of recombinant Tat protein (lanes 1-3), or 200,400 ng of GST-Tip110 protein (lanes 4, 
5), or 100 ng of Tat protein together with 200, 400 ng of GST-Tip110 protein (lanes 6, 7). 
The ratio of the PCR products from long transcripts to those from the short transcripts 
was calculated and used as the elongation efficiency. 
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Figure 22. Effects of Tip110 knock down on HIV-1 transcription elongation      
(A) Immundepletion of Tip110 from Hela nuclear extract.  Western blotting was then 
performed for undeleted, IgG and Tip110 depleted nuclear extract.  Specific antibodies 
against Tip110 and β-actin were used to demonstrate the depletion efficiency.  (B) 
Transcription elongation reactions were performed with indicated nuclear extracts, 200ng 
Tat protein, and the HIV-1 LTR G-less template.  Lane 3 had 200 ng GST-Tip110 added 
back to the transcription reaction.  (C) 293T cells were first transfected with pSIREN or 
psh-Tip110 (day 0) and then transfected with HIV-1 G-less template or pTat.myc plasmid 
at day 4 and 7.  Cells were harvested on day 7 and10 for cell lysates and Western 
blotting for Tip110, Tat and β-actin.  (D) RNA was extracted from the indicated cells; 
RT-PCR was performed for long and short transcripts.    
105 
 
PART II: Tip110 interacts with hnRNP A1 and regulates HIV-1 alternative splicing  
 
2.1 
During our study to define the synergistic effect of Tip110 and Tat on LTR transcription, 
we determined whether Tip110 enhanced HIV-1 gene expression and replication through 
direct alteration of HIV-1 gene expression profile such as Tat.  To address this possibility, 
multiplex RT-PCR was performed to compare the mRNA expression profile between 
cells with and without Tip110 over-expression.  Thus, 293T cells were transfected with 
pNL4-3 and pTip110.GFP or pEGFP as a control.  The cells were harvested and first 
prepared for Western blotting to confirm Tip110 expression (Fig. 23A). Then, RNA from 
these cells was isolated and RT-PCR was performed with a primer pair BSS-SJ4.7, which 
have been used to amplify all multiply spliced mRNA (Markus Neumann 1994).  
Following the first round of RT-PCR reaction, 5 μl of the PCR reaction were added with 
32P-dCTP and continued for additional three PCR cycles.  The products were then 
separated by denaturing gel electrophoresis.  The results showed an increased level of 
one PCR product corresponding to tat mRNA in Tip110-expressing cells (Fig. 23B).  To 
verify that the PCR product of interest was derived from tat mRNA, we recovered the 
DNA; PCR cloned it, and sequenced it.  The sequencing results confirmed that this 
product corresponded to tat exon2.  This was the first evidence to suggest that Tip110 
enhancement of HIV-1 gene expression and replication likely also involved preferential 
regulation of tat mRNA expression.  
Tip110 alters HIV-1 mRNA splicing pattern 
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Figure 23. Alteration of HIV-1 mRNA splicing by Tip110  (A)293T cells were 
transfected with pNL4-3 and pTip110.GFP or pGFP-N3.  Thirty six hours 
post-transfection the cells were harvested and performed Western blotting against Tip110 
or β-actin.  (B) Total RNA was isolated, reverse transcribed and then PCR was carried 
out with primers BSS and SJ 4.7.  Five microliter of amplification products were added 
32PdCTP for additional three PCR cycles, and separated by denaturing gel electrophoresis. 
GAPDH RT-PCR was included as a control.  
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2.2 Tip110 preferentially increases tat transcripts 
To further confirm multiplex RT-PCR results, we wished to perform RT-PCR with 
tat-specific primers (Fig. 24A).  However, because tat transcripts are multiply spliced 
and shared common regions with singly spliced and unspliced mRNA, RT-PCR cannot 
specifically amplify tat transcripts.  To overcome this problem, pHIV-Rev-plasmid was 
used in place of pNL4-3 in the transfections, as Rev deletion would retain singly spliced 
and unspliced mRNA in the nucleus and only multiply spliced mRNA was present in the 
cytoplasm.  Thus, transcription of cells with pHIV-Rev-, followed by subcellular 
fractionation would allow us to use RT-PCR to determine Tip110 effects on tat mRNA 
expression.  The cells were first transfected with pHIV-Rev-and pTip110.HA orpcDNA3 
and then performed subcellular fractionation which was assessed by Western blotting 
against nuclear protein PCNA.  Compared to whole cell lysates, the cytoplasmic fraction 
had much less PCNA (Fig. 24B).  Then, RNA was extracted from both cytoplasmic 
fractions and whole cell lysates and RT-PCR was performed with tat-specific primers.  
GAPDH was amplified as a control.  Using the cytoplasmic fraction RNA, RT-PCR 
reactions with primers TAR5/ Tat 21 or Tat 5/ Tat 3C have increased amplified products 
with Tip110 over-expressing, while the products amplified by GAPDH primer showed no 
change (Fig. 24C, left panel).  Using the whole cell RNA, RT-PCR amplified products 
remained the same with tat primers or GAPDH primer (Fig. 24C, right panel), indicating 
Tip110 preferentially increased tat transcripts, but not singly or unspliced mRNA.  By 
three independent experiments, Tip110 increased tat transcripts by more than 1.6 fold, 
which confirmed our previous conclusion that Tip110 preferentially increased tat mRNA. 
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Figure 24. Increased tat mRNA expression by Tip110  (A) Schematic of HIV-1 tat 
exons and the primer pairs for RT-PCR.  (B) 293T cells were transfected with HIV-Rev- 
plasmid with pTip110.HA or pcDNA3.The cells that were only transfected with pcDNA3 
were used as a control.  Two days after transfection, cytoplasmic fractions were 
prepared and Western blots for nuclear protein PCNA, Tip110 or β-actin were performed. 
(C)RNA was extracted from cytopolasmic fraction or whole cell lysates followed by 
reverse transcription.  PCR was performed with primers TAR5’/ Tat21 or Tat5/ 
Tat3C.GAPDH RT-PCR was included as a loading control.  RT-PCR products were 
quantitated by densitometry, and the data were means ± S.D. and representative of three 
independent experiments.  * p<0.05, ** p<0.01. 
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2.3 Tip110 increases Tat protein expression 
To further confirm that Tip110 effects on Tat protein expression resulted from HIV-1 
RNA splicing, we took advantage of tat minigene that only contains three exons and does 
not undergo alternative splicing to generate tat mRNA (Fig. 25A).  293T cells were 
transfected with pNL4-3 or the tat minigene, along with pTip110.HA and performed 
Western blotting against Tip110, Tat and β-actin.  With Tip110 overexpression, Tat 
protein expression increased by 1.6 fold in pNL4-3-transfecteced cells but remained 
unchanged in tat minigene transfected cells (Fig. 25B).  These results further confirmed 
that Tip110 increasesed tat mRNA and Tat protein expression through regulation of 
HIV-1 RNA alternative splicing.    
 
2.4 Tip110 enhances tat exons 1-2 splicing but not tat exons 2-3 splicing 
Tat mRNA splicing is regulated by acceptor splice site A3and A7 as well as the ESE or 
ESS cis-element within tat exon 2 or tat/rev exon3 (Si, Rauch et al. 1998; Zahler, 
Damgaard et al. 2004).  To determine which tat splice site Tip110 regulated, we took 
advantage of two sets of tat pre-mRNA minigenes.  The first setpCMV-HS1-WT and 
pCMV-ESS2-M contains tat exon 1, exon 2, and a shortened intron and have been used to 
study the regulation of A3 splicing site (Si, Amendt et al. 1997).  pCMV-HS1-WT 
contains wild-type ESS2, while pCMV-ESS2-M has 4 nt mutation from 4748 to 5152 in 
the ESS core sequence (Fig. 26A).  The second set pCMV-HS2contains tat exons 2 and 
3, with the putative ESS and ESE elements located in tat exon3 and has been used to 
study regulation of the A7 splice site (Si, Rauch et al. 1998) (Fig. 28A).  We constructed  
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Figure 25. Enhancement of Tat protein expression by Tip110  (A) Schematic of 
NL4-3 proviral DNA and intronless tat minigene.  (B) 293T cells were transfected with 
tat minigene (left panel) or pNL4-3 (right panel) with or without pTip110.HA.  The 
cells were harvested 48 hr after transfection, lysed in RIPA buffer, and 20 μg of each 
sample were separated by SDS-PAGE followed by Western blot analysis using 
anti-Tip110, anti-Tat, or anti-β-actin.  Tat expression was quantitated by densitometry 
and expressed as fold increase over the control (Rel.). 
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these two sets of minigenes under the CMV promoter from the original cassettes, so in 
vivo splicing assay could be performed by transfection, isolation of the RNA from the 
transfected cells followed by RT-PCR. 
 
pCMV-HS1-WT or pCMV-ESS2-M minigenes were first used to test the function of 
Tip110 in tat exons 1-2 splicing.  293T cells were transfected with pCMV-HS1-WT or 
pCMV-ESS2-M and total RNA was extracted after 3 days.  RT-PCR was later performed 
with primers T7/ tat 37, and both unspliced and spliced RT-PCR products were detected 
at the expected sizes (Fig. 26B).  As expected, ESS2-M showed a 1.6 folds increase in 
splicing efficiency over WT (Si, Amendt et al. 1997).  To further validate this new in 
vivo transcription/splicing protocol, 293T cells were co-transfected withpCMV-HS1-WT 
or pCMV-ESS2-M and increasing amounts of phnRNP A1-GFP, which has been shown to 
interact with UAG sequence in ESS2 and inhibit upstream 3’ss splicing (Caputi, Mayeda 
et al. 1999).  The results showed that hnRNP A1 expression led to less spliced RT-PCR 
products from WT but no changes from ESS2-M (Fig. 26C).  Then, the cells were 
transfected with pCMV-HS1-WT or pCMV-ESS2-M and increasing amounts of 
pTip110.HA.  The results showed that Tip110 expression increased the spliced RT-PCR 
products from WT (Fig. 27A) and no changes in ESS2-M (Fig. 27B), suggested Tip110 
enhanced tat exons 1-2 splicing and ESS2 was directly involved.   
 
Next, we performed similar experiments with tat exons 2-3 minigene pCMV-HS2 and 
ASF/SF2 was included as a positive control.  As expected, ASF/SF2 showed positive 
effects in tat exons 2-3 splicing (Fig. 28B), which was consistent with previous reports 
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that ASF/SF2 stimulates tat exons 2-3 splicing in an ESE3-dependent manner (Ropers, 
Ayadi et al. 2004).  However, when pCMV-HS2 was co-transfected with increasing 
amounts of pTip110.HA, tat exons 2-3 splicing showed no changes (Fig. 28C), indicating 
Tip110 did not affect tat exons 2-3 splicing. 
 
2.5 Tip110 knockdown decreases tat exons 1-2 splicing 
To further determine the significance of Tip110 protein in tat mRNA splicing, we 
down-modulated endogenous Tip110 expression and determined its effects on tat mRNA 
splicing.  We constructed pshTip110 plasmid to express Tip110-specific shRNA and first 
tested the efficiency of pshTip110 in decreasing endogenous Tip110 expression.  A 
transfection timeline was devised for these multiple transfection experiments (Fig. 29A). 
293T cells were first transfected with pshTip110plasmid or pSIREN backbone vector; the 
cells were harvested on day 3, 6, 10 after transfection.  Western blotting analysis 
demonstrated that endogenous Tip110 protein expression was down-modulated by 
pshTip110in day 6 after transfection but showed some recovery at day 10 (Fig. 29B).  
As a control, 293T cells were transfected with the backbone vector pSIREN, and Tip110 
expression showed no significant changes (Fig. 29B).  Then, we transfected pCMV-HS1 
or pCMV-HS2 plasmids into 293T cells on day 4 or day 7 following pshTip110 or 
pSIREN transfection (Fig. 29A).  The cells were harvested at day 7 or day 10 for RNA 
isolation and RT-PCR analysis.  In parallel with Tip110 expression, tat exons 1-2 
splicing efficiency was decreased at day 7 and began to increase at day 10 (Fig. 30A).  
In contrast, tat exons 2-3 splicing showed no changes (Fig. 30B).  Taken together, these  
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Figure 26. pCMV-WT and pCMV-ESS2-M minigene and their splicing          
(A) Schematic of pCMV-WT and pCMV-ESS2-M minigene constructs and RT-PCR 
primers.  (B) Minigene splicing: 293T cells were transfected with 2 μg of pCMV-WT or 
pCMV-ESS2-M.  Total RNA was extracted and processed for RT-PCR.  The RT-PCR 
products were determined by densitometry, the ratio of spliced to unspliced ones were 
calculated and set to 1 in the pCMV-WT-transfected cells.  (C) pCMV-WT (left panel) 
or pCMV-ESS2-M (right panel) were transfected into 293T cells in the combination of 
increasing amount of hnRNPA1-GFP (0, 0.5, 1.0 μg).  Western blotting was performed 
for GFP or β-actin expression.  RT-PCR was performed to determine the unspliced and 
spliced transcripts.  The ratio of spliced to unspliced RT-PCR products was calculated.  
These data were mean ± SD and representative of three independent experiments.        
* p<0.05, ** p<0.01.u: unspliced band, s: spliced band.  
 
 
  
119 
 
 
 
 
 
 
 
 
 
  
120 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27. Increased tat exons 1-2 splicing by Tip110  pCMV-WT(A) or 
pCMV-ESS2-M (B) were transfected into 293T cells in combination with increasing 
amounts of pTip110.HA ( 0, 0.5,1.0 μg).  Cell were harvested for cell lysates and 
Western blotting against Tip110, β-actin, or for RNA and RT-PCR to amplify tat exons 
1-2 unspliced and spliced transcripts.  The ratio of spliced to unspliced RT-PCR 
products was calculated as before. * p<0.05, ** p<0.01.u: unspliced band, s: spliced 
band. 
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Figure 28. Tip110 effects on tatexons 2-3 splicing  (A)Schematic of pCMV-HS2 
minigene construct.  (B) 293T cells were transfected with pCMV-HS2 and increasing 
amounts of ASF/SF2 (0, 0.5, 1.0 μg) and processed as described above.  (C) 293T cells 
were transfected with pCMV-HS2 and increasing amount of Tip110 (0, 0.5, 1.0 μg) and 
processed as described above.  u: unspliced band, s: spliced band. 
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Figure 29. Tip110 knockdown  (A) The transfection timeline. (B) 293 T cells were 
transfected with pSIREN or psh-Tip110 plasmid and harvested at day 0, 3, 6, and 10 for 
western blotting analysis against Tip110 or β-actin. 
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Figure 30. Decreased tat exons 1-2 splicing by Tip110 knockdown  293T cells were 
first transfected with pSIREN or psh-Tip110 (day 0) and then transfected with 
pCMV-HS1 (A) or pCMV-HS2 (B) at day 4 and 7.  Cells were harvested on day 7 and 
day 10 for cell lysates and Western blotting or RNA and RT-PCR.  u: unspliced band, s: 
spliced band. 
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results confirmed that Tip110 preferentially increased tat exons 1-2 but not tat exons 2-3 
splicing. 
 
2.6 HAT and RRM domains are involved in Tip110-mediated tat mRNA splicing 
To determine which functional domains of Tip110 were important for Tip110-mediated 
tat mRNA splicing, we took advantage of a series of Tip110 mutants which contained 
RRM domain, C-terminal domain, NLS domain or HAT domain deletions (Fig. 13A).  
Due to differences in antibody epitopes, the Tip110 mutants divided into two groups for 
Western blotting detection: ∆RRM, ∆NLS, and ∆CT mutants were detected by anti-156 
serum, and ∆NT was detected by Tip110 monoclonal antibody.  293T cells were first 
transfected with each of the Tip110 mutants and pHIV-Rev- plasmid and then harvested 
for cytoplasmic lysates.  Expression of Tip110 and its mutants and the efficiency of 
cytoplasmic fractionation were confirmed by Western blotting against Tip110 and PCNA, 
respectively (Fig. 31A).  Then, RNA from the cytoplasmic lysates as well as whole cell 
lystate was isolated and RT-PCR was performed for tat exon 2.  GAPDH RT-PCR was 
included as a loading control.  We found that deletion of the HAT and RRM domain of 
Tip110 reduced tat exon 2 mRNA expression to the basal level but the deletion of NLS 
domain had tat exon 2 transcripts close to the wild-type Tip110 (Fig. 31B).  Later, 
similar results were obtained with minigene pCMV-HS1 (Fig. 32).  Taken together, 
these results showed HAT and RRM domains of Tip110 were involved in 
Tip110-mediated tat mRNA splicing.  
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Figure 31. Tip110 domains involved in tat mRNA splicing  293T cells were 
transfected with Tip110 or each of its mutants.  pcDNA3 was included as a control.  
Two days after transfection, cells were harvested for cytoplasmic and whole cell lysates 
and Western blotting (A), or RNA and RT-PCR with primers tat5/ tat3C to amplify tat 
exon 2 (B).  GAPDH RT-PCR was included as a loading control. W: whole cell lysate.  
C: cytoplasmic fraction lysate.   
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Figure 32. Tip110 domains involved in tat exons 1-2 splicing  (A) 293T cells were 
transfected with pCMV-WT and Tip110 or its mutants.  Expression of Tip110 and its 
mutants was determined by Western blotting.  (B) RNA was extracted for RT-PCR to 
amplify spliced/unspliced transcripts from tat exons 1-2 minigene as above.  The bar 
graph represents mean values ± SD of the spliced/unspliced ratio from three independent 
experiments.  u: unspliced band, s: spliced band. 
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2.7 Tip110 directly binds to hnRNP A1 in vitro 
We next attempted to determine the molecular mechanisms for Tip110-mediated tat 
exons 1-2 splicing.  A separate study from our own group has recently identified a 
number of Tip110-interacting proteins (Table. 2).  Among these proteins was hnRNP A1, 
which has been shown to inhibit tat exons 1-2 splicing through ESS2 element (Caputi, 
Mayeda et al. 1999).  Our result above showed that Tip110 enhanced tat exons 1-2 
splicing through ESS2 element.  Thus, we hypothesized that Tip110 interacted with 
hnRNP A1 and subsequently impaired hnRNP A1 interaction with the ESS2 element 
within tat exon 2.  To test this hypothesis, we first prepared recombinant GST-hnRNP 
A1 and Tip110 proteins and performed in vitro GST pull down assay.  We confirmed the 
MASS data that Tip110 directly bound to hnRNP A1 (Fig. 33).   
 
2.8 Tip110 interaction with hnRNPA1in vivo 
To further confirm Tip110 interaction with hnRNP A1, 293T cells were transfected with 
phnRNP A1-GFP and pTip110-HA and immunoprecipitation and Western blotting 
analysis was performed.  To our surprise, no hnRNP A1 in either anti-Tip110 or anti-HA 
immunoprecipitates could be detected (Fig. 34A).  In addition, no Tip110 was detected 
in anti-GFP or anti-hnRNP A1 immunoprecipitates (Fig. 34B).  Then, the input amount 
of cell lysate was increased by transfection of 10 times more cells.  The cell lysate was 
passed through a HA-conjugated affinity matrix column to enrich the Tip110 protein, and 
the Tip110 protein was then eluted with a competitive HA peptide and analyzed for the 
presence of hnRNP A1 protein by Western blotting.  The results showed the presence of 
hnRNP A1 protein in the elution (Fig. 34C, right panel), as well as Tip110 protein (right 
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panel), suggested Tip110 interacted with hnRNP A1 in a weak or transient manner in 
vivo.  
 
2.9 Tip110 does not bind to tat mRNA 
Tip110 is predicted to contain two RNA recognition motifs (RRM) (Fig. 14A) and it may 
bind to RNA.  Thus, we also examined the possibility that Tip110 bound to the ESE2 or 
ESS2 RNA cis-element within tat exon 2 by a gel shift assay.  RNA probes were in vitro 
transcribed from T7 promoter and purified (Fig. 35A) and recombinant hnRNP A1-GST 
protein was include as a positive control in this assay.  As expected, hnRNP A1 formed a 
complex with WT RNA (Fig. 35B, lanes 3, 4), but not with E2-M RNA (lanes 7, 8).  
Then, Tip110-GST protein was incubated with WT or E2-M RNA, and no protein-RNA 
complex detected with either WT or E2-M RNA (Fig. 35C).  To test the possibility that 
Tip110 complexed with tat mRNA through other proteins, nuclear extract was used in 
place of recombinant protein in the gel shift assay with the WT and E2-M RNA.  When 
WT was used as a probe, incubation with nuclear extract led to formation of multiple 
complexes of RNA with cellular proteins, which was shown as a smear (Fig. 35D, lane 4).  
Inclusion of anti-hnRNP A1 antibody resulted in formation of a distinct complex, 
presumably among hnRNP A1, WT RNA and anti-hnRNP A1 antibody (lane 5).  
However, inclusion of anti-Tip110 antibody showed no apparent change in the gel shift 
pattern (lane 6).  In contrast, when E2-M RNA was used as a probe, inclusion of either 
anti-Tip110 or anti-hnRNP A1 antibody showed no changes in the gel shift pattern (Fig. 
35E).  Taken together, these results further confirmed that Tip110 did not directly bind 
to ESE2 or ESS2 cis-element within tat exon 2.   
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Table 2.Tip110 interacting proteins 
Name  M.Wt Peptides 
Main protein 
1. SART 3 
 
109865 
 
51 peptides 
Cytoskeleton proteins 
1. Actin 
2. Keratin 1-Cyt1 
3. Keratin 1-Cyt9 
4. Keratin 2-Cyt2 
5. Keratin 1-Cyt10 
6. Keratin 1-Cyt10 
7. Tubulin beta 
8. Tubulin alpha 
9. Synaptotagmin 2-a 
 
41710 
65978 
62092 
65825 
59475 
57213 
49799 
50062 
42709 
 
19  peptides 
12  peptides 
9  peptides 
4  peptides 
5  peptides 
5  peptides 
3  peptides 
2  peptides 
1 peptides 
Transportation protein 
1.  Importin 2 alpha 
 
57826 
 
3  peptides 
Heat shock proteins 
1.  HSP A8 
2.  HSPA1B 
 
70845 
70009 
 
5  peptides 
6  peptides 
Ribonucleoproteins 
1. hnRNPA2-B1 
2. hnRNPA1 
3. hnRNP U 
 
28394 
38822 
88924 
 
1  peptides 
3  peptides 
2  peptides 
YB-1 protein 
1.Nulease-sensitive element-binding protein1  
 
35903 
 
1  peptides 
Skin protein 
1. Hornerin 
2. Filaggrin 
 
282228 
434922 
 
6  peptides 
4  peptides 
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Figure 33. Direct interaction between Tip110 and hnRNP A1 protein in vitro 
Tip110 protein (4 μg) was prepared by thrombin cleavage of GST-Tip110 and then 
purified by glutathione beads to eliminate the GST protein.  Meanwhile, 2 μg 
GST-hnRNP A1 and GST protein were immobilized onto glutathione beads and incubated 
with purified Tip110 protein at 4oC overnight.  After washing, the protein from GST 
beads (lane 2) and GST-hnRNP A1 (lane 3) were analyzed by Western blotting for Tip110 
(upper panel) or GST (lower panel); Purified Tip110 protein was included as the size 
marker (lane 1). 
  
141 
 
 
 
 
 
 
 
 
  
142 
 
 
 
 
  
143 
 
 
 
 
 
 
 
 
Figure 34. Tip110 interaction with hnRNP A1 protein in vivo  (A) Cell lysates from 
293T cells transfected with 10μg pTip110-HA and 10μg phnRNPA1-GFP were 
immunoprecipitated with Tip110 (left panel), anti-HA antibody (right panel) or mouse 
IgG followed by Western blotting against GFP.  Western blotting for Tip110 or HA 
against Tip110 or HA immunoprecipitates was also performed as the positive control.  
(B) Cell lysates were first immunoprecipitated with anti-hnRNP A1 or anti-GFP, followed 
by Western blotting for Tip110.  Western blotting with anti-hnRNP A1 or anti-GFP 
against hnRNP A1 immunoprecipitates were performed as the control.  (C) 293T cells 
(5x10cm plates) were transfected with phnRNPA1.GFP and pTip110.HA.  
hnRNPA1.GFP and Tip110.HA expression were first verified by Western blotting 
analysis with anti-Tip110 and anti-GFP antibody (upper panel).  The cell lysate were 
passed through anti-HA-affinity matrix column; bound proteins were eluted and analyzed 
by Western blotting for Tip110 or hnRNPA1-GFP (lower panel).  
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2.10 Tip110 blocks the interaction between hnRNP A1 and ESS2 cis-element 
The most important parameter for site A3 activation and tat exons 1-2 splicing is binding 
of SC 35 or SRp 40 to ESE2 and subsequent displacement of hnRNP A1 from ESS2 
(Hallay, Locker et al. 2006).  Thus, we speculated that Tip110 functioned to activate tat 
exons 1-2 splicing through its interaction with hnRNP A1 and as a result, impeded 
binding of hnRNP A1 to ESS2.  To test this possibility, gel shift assay was performed to 
determine the interaction between hnRNP A1 and WT RNA in the presence of Tip110.  
As before, hnRNP A1 complexed with WT RNA probe (Fig. 36A, lane 2).  But when 
purified recombinant GST-Tip110 protein was included, there was a dose-dependent 
inhibition in the formation of the hnRNP A1-WT RNA complex (Fig. 36A, lanes4-6).  
In contrast, GST protein showed no effects in the complex formation (Fig. 36A, lane 3).  
These results demonstrated that Tip110 impeded the complex formation between hnRNP 
A1 and ESS2.  To further confirm this inhibition effect in vivo, supershift assay was 
performed with nuclear extracts and increasing amount of Tip110-GST protein.  The 
supershifted complex was detected by adding anti-hnRNP A1 antibody (Fig. 36B, lane4) 
and decreased with increasing amounts of Tip110-GST protein (Fig. 36B, lanes 6-8).  
These results further confirmed that Tip110 blocked the complex formation of hnRNP A1 
with tat ESS2 and suggested the interaction among Tip110, hnRNP A1 and tat ESS2 
likely accounted for Tip110-mediated tat exons 1-2 splicing.  
145 
 
 
 
 
 
 
 
 
 
  
146 
 
 
 
 
 
 
 
 
 
 
 
 
  
147 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35. No interaction between Tip110 and ESE2/ESS2 RNA  (A) The WT RNA 
and ESE2 (E2-M) RNA used for gel shift assay.  (B) About 10 pmoles (20000cpm) of 
WT RNA or E2-M RNA probes were incubated in a 20μl reactions containing 0, 50,100 
ng hnRNPA1-GST or 200ng GST protein.  (C) 0,100,200ng of Tip110-GST or 200ng 
GST protein was incubated with WT RNA or E2-M RNA.  (C) and (D) Nuclear extract 
(1 μl) was used in place of recombinant proteins to bind WT or E2-M RNA on ice for 
15min.  Then, 1 μl anti-hnRNP A1 (4B10) or anti-Tip110 (1C4H6) was added to the 
reaction and continued for 15 min on ice, followed by gel electrophoresis.  As negative 
controls, RNA was only incubated with antibodies but without nuclear extract.  F: free 
probe; C: RNA-protein complex; S: RNA-protein-antibody supershifted complex.  
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Figure 36. Inhibition of complex formation between hnRNP A1 and ESS2 by Tip110 
(A) hnRNP A1-GST protein (100 ng) was incubated with 10 pmoles (20000 cpm) of 
32P-labeled WT RNA probes in the presence of and 0 ng (lane2), 50 ng (lane 4), 100 ng 
(lane 5), or 200 ng (lane 6) recombinant Tip110-GST protein or 200 ng GST protein 
(lane 3), and the complex formation of hnRNP A1 and WT RNA was determined by gel 
shift assay. RNA probe only was detected in the absence of hnRNPA1-GST protein (lane 
1).  (B) 1μl nuclear extract with 200 ng GST (lane 5), or 0 ng (lane 4), 50 ng (lane 6), 
100 ng (lane 7), 200 ng (lane 8) were incubated with 10 pmoles 32P-labeled WT RNA 
followed by adding 1μl anti-hnRNP A1 into the reaction.  The RNP complex formed 
without adding anti-hnRNP A1 (lane 3) or RNA incubated with only antibody (lane 2) or 
RNA only (lane1) were included as controls.  F: free probe; C: RNA-protein complex; S: 
RNA-protein-antibody supershifted complex. 
 
151 
 
DISCUSSION 
 
Summary of the results 
The transcriptional activation of the HIV-1 LTR promoter is a complex series of events 
and needs coordinated interactions of viral and cellular proteins.  HIV-1 Tat is the key 
transactivator of HIV-1 transcription and promotes the formation of transactivational 
complexes at the LTR promoter.  Besides Tat, a large number of cellular factors are also 
involved in the transcription.  These factors either function by removing inhibitory 
molecules which block RNAPII phosphorylation in the LTR promoter or recruiting the 
elongation competent RNAPII-containing complexes to the LTR promoter (Baillat, 
Hakimi et al. 2005; Vaness Bres Nathan Gomes and Jones 2005; Vardabasso, Manganaro 
et al. 2008) 
 
In this study, we focused on Tat-interacting Protein of 110kDa, Tip110.  Studies from 
our group have shown that Tip110 synergies with Tat in transactivation of the HIV-1 LTR 
promoter, increases viral gene expression and virus production (Liu, Li et al. 2002).  
However, the underlying molecular mechanisms were not understood and are the focus of 
the dissertation research.   
 
We first confirmed that Tip110 significantly enhanced HIV-1 gene expression and viral 
production.  This enhancement was at least in part due to their synergetic transactivation 
of the LTR promoter transactivation (Fig. 7).  HIV-1 gene expression from proviral 
DNA transfection did not alter endogenous Tip110 expression (Fig. 8).  To examine how 
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Tip110 enhanced Tat-mediated LTR transactivation, we then determined if Tip110 
interacted with known transcription factors involved in activation of HIV-1 LTR promoter.  
We found that Tip110 was complexed with unphosphorylated form (RNAPIIa) but not 
phosphorylated form (RNAPIIo) of RNAPII (Fig. 10 & 11).  The specific and direct 
interaction between Tip110 and RNAPIIa was confirmed by GST pull-down assay and 
mutagenesis analysis (Fig. 12 & 13).  Although Tip110 did not interact with cyclin T1 or 
CDK9 (Fig. 14 & 15), it interaction with Tat and RNAPIIa led to more P-TEFb 
recruitment to the transcription complex (Fig. 16).  Since P-TEFb was responsible for 
RNAPII serine 2 phosphorylation, we further found that RNAPII serine 2 
phosphorylation was increased when Tip110 and Tat were co-expressed (Fig. 17).  ChIP 
assays confirmed that Tip110 was present within the HIV-1 LTR promoter and associated 
with increased recruitments of P-TEFb to the promoter, which further led to the increased 
phosphorylation of serine 2 within the RNAPII CTD at the LTR promoter (Fig. 19 & 20).  
Consistent with these findings, we showed that Tip110 expression was direct correlated 
with transcription elongation of the LTR promoter (Fig. 21 & 22).  
 
During these studies, we noticed that Tip110 expression let to increased tat mRNA 
production (Fig. 23 & 24), as well as Tat protein expression (Fig. 25).  in vivo splicing 
assay with tat minigene showed that Tip110 preferentially increased tat exons 1-2 
splicing by activating HIV-1 A3 splicing site but had no function in tat exons 2-3 splicing 
(Fig. 27 & 28), and that the preferential activity of Tip110 was mediated by ESS2 but was 
not involved interaction between Tip110 and ESE2 or ESS2 RNA(Fig. 35).   
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Affinity purification followed by 2D Mass from a separate study in our lab indicates 
hnRNP A1, a negative splicing regulator binding to ESS2 cis-element to complex with 
Tip110 (Table 2).  Thus, we performed additional experiments and confirmed this 
interaction both in vitro and in vivo (Fig. 33 & 34).  Gel shift assay showed that Tip110 
binding to hnRNP A1 blocked the formation of hnRNP A1-ESS2 complex (Fig. 36), and 
this likely accounts for Tip110-association activation of A3 splice site and preferential 
expression of tat mRNA and Tat.  Taken together, our studies suggest that Tip110 plays 
important roles in both LTR transcription elongation and HIV-1 pre-mRNA splicing and 
as a result regulates HIV-1 viral gene expression and viral replication  
 
The interaction between Tip110 and transcription factors 
A large number of cellular factors are involved in the Tat-mediated transcription by 
recruiting the elongation competent RNAPII-containing complexes and/or interacting 
with multiple transcription factors.  For example, SKIP, Tat-SF1 and CA150 are 
associated with Tat:P-TEFb in nuclear extracts and present in large RNAPII elongation 
complexes (Zhou and Sharp 1996; Carty, Goldstrohm et al. 2000; Vaness Bres Nathan 
Gomes and Jones 2005).  Tip110 was first identified as a Tat interacting protein through 
the yeast two-hybrid screening of a human fetal brain cDNA library, with Tat as bait.  
Further studies have confirmed this direct interaction by immunoprecipitations well as 
GST pull-down assay (Liu, Li et al. 2002).  
 
We found that Tip110 bound to unphosphorylated RNAPII (CTDa) but not its 
phosphorylated form (CTDo) by immunoprecipitation followed by Western blotting (Fig. 
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10 & 11).  This direct and specific binding was further supported by the GST pull-down 
assay and mutagenesis analysis and recruited the HAT domain of Tip110 (Fig. 12 & 13).  
Protein structure analysis predicted that the N-terminal two-thirds of the Tip110 protein 
contain seven HAT motifs.  These HAT motifs provide a structural unit of two 
antiparallel α-helices that form functional TPR(s) that determine the specificity of 
protein-protein interaction (Blatch and Lassle 1999).  Besides binding to 
unphosphorylated RNAPII, the HAT domain is also responsible for Tip110 interaction 
with Tat (Liu, Li et al. 2002).  It is likely that Tip110 formed a complex with Tat and 
unphosphorylated RNAPII through the same N-terminal domain to stabilize the mega 
transcription complex.  In addition, HAT domain is involved in Tip110 interaction with 
a C-terminal region of the U4/U6 snRNP-specific 90K protein which functions in the 
reassembly of the U4/U6 snRNP(Bell, Schreiner et al. 2002; Medenbach 2004).  The 
HAT domain is also involved in Tip110 interaction with RNPS1 (Harada, Yamada et al. 
2001).  These results confirm that suggesting HAT domain controls the specificity of 
Tip110 protein-protein interaction. 
 
The recruitment of P-TEFb to the transcription complex by Tip110 and Tat 
Although Tip110 and P-TEFb are co-localized in the nuclear speckle area (Herrmann and 
Mancini 2001), our data showed no interaction between Tip110 and P-TEFb (Fig. 14 & 
15).  This phenomenon distinguishes Tip110 with other cellular transcription factors 
such as SKIP , which associates with P-TEFb and is recruited to the LTR promoter by Tat 
(Vaness Bres Nathan Gomes and Jones 2005); or ELL2, a newly found elongation factor 
in the P-TEFb complex and Tat functions to bring more ELL2 to P-TEFb and helps to 
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stabilize ELL2 and active P-TEFb (He, Liu et al. 2010).  There is no direct interaction 
between Tip110 and P-TEFb (Fig. 14 & 15), but Tip110 is capable of recruiting more 
P-TEFb to the transcription complex in the presence of Tat (Fig. 16).  Therefore, we 
speculate that Tip110 is first recruited to the unphosphorylated RNAPII on the LTR 
promoter in the absence of Tat and then interacts with Tat to recruit more P-TEFb, and 
becomes dissociated from the transcription elongation complex following P-TEFb 
phosphorylation of RNAPII.   
 
Since P-TEFb is responsible for RNAPII serine 2 phosphorylation, we set out to 
investigate whether Tip110 would change the RNAPII phosphorylation level.  Our data 
showed that Tip110 protein alone decreased the level of unphosphorylated RNAPII while 
increased the level of both serine 2 and serine 5 phosphorylated RNAPII by 2 fold, 
suggesting that Tip110 was a weak transactivator for HIV-1 LTR basal level transcription 
(Fig. 17).  When Tip110 and Tat were co-expressed, both serine 2 and serine 5 
phosphorylations of RNAPII were considerably increased, with a more decrease in 
unphosphorylated RNAPII (Fig. 17).  P-TEFb also regulates expression of several 
cellular genes at the transcription elongation stage, including hsp70, the proto-oncogenes 
c-myb, c-myc and c-fos (Rougvie and Lis 1988; Krumm, Meulia et al. 1992; Roberts, 
Purton et al. 1992).  The RNAPII complexes are stalled in the 5’ region of the 
transcription unit for these genes, P-TEFb recruitment is the key regulator that helps 
RNAPII to overcome this rate-limiting step.  TATA-box instead of TAR structure is 
important for the recruitment of P-TEFb (Montanuy, Torremocha et al. 2008).  
Therefore, the increased phosphorylated form of RNAPII may result from the recruitment 
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of P-TEFb by Tip110 and Tat to the promoters of these cellular genes.  In order to 
examine the RNAPII phosphorylation on the LTR promoter, we can label LTR-promoter 
templates 5’ end with biotin and then isolated LTR bounded PICs to detect protein 
components of the LTR PIC (Zhou, Halanski et al. 2000).  By this method, we would 
expect to see more increase in RNAPII phosphorylation located on the HIV-1 LTR 
promoter in the presence of Tip110 and Tat.  
 
Tip110 is present on the LTR promoter 
HIV-1 transcription is regulated by interplay between a combination of viral and cellular 
transcription factors with binding sites in the HIV-1 LTR promoter.  With ChIP assay, 
we first detected Tip110 on the transient LTR promoter by transfecting pNL4-3 into 293T 
cells (Fig. 19).  To further examine if Tip110 was recruited to the integrated LTR 
promoter in the absence of Tat, we performed ChIP assay in U373-MAGI or CEM-GFP 
cells.  In these cell lines, either the LTR promoter-driven Lac Z reporter gene 
(U373-MAGI) or the LTR promoter-driven GFP reporter gene (CEM-GFP)is stably 
integrated into the chromosome (Gervaix, West et al. 1997; Brockman, Tanzi et al. 2006; 
Sundaravaradan, Das et al. 2007).  The results showed that endogenous Tip110 was 
present on the integrated LTR promoter in the absence of Tat (Fig. 19), indicating that the 
Tip110 was recruited to the LTR promoter. 
 
The ChIP assay also showed that P-TEFb were only recruited to the LTR promoter only 
when Tat was expressed and showed a significant increasing with Tip110 expression (Fig. 
19).  These results were consistent with previous Western blot result that more P-TEFb 
157 
 
were recruited to the transcription complex in the presence of Tip110 (Fig. 16).  We 
observed 3 fold increases of cyclin T1 compared to 1.5 fold increase of CDK9, which 
was probably because Tat directly interacted with Tip110 and cyclin T1 and mediated 
Tip110 recruitments of cyclin T1.  Besides P-TEFb, we further examined the RNAPII 
phosphorylation level at the LTR promoter by ChIP assay.  Ser 2 phosphorylation of 
RNAPII only occurred in the presence of Tat and increased by about 2 folds with Tip110 
overexpression, which may result from the increased recruitment of P-TEFb by Tip110 
and Tat (Fig. 16).  Unphosphorylated and serine 5 phosphorylated RNAPII were readily 
detected at the HIV-1 promoter in the absence of Tat, while Tip110 with Tat only had 
slightly effect on the serine 5 phosphorylation (Fig. 16), which was consistent with 
previous studies that TFIIH is recruited to the LTR promoter for RNAPII serine 5 
phosphorylation in the absence of Tat (Chen and Zhou 1999).   
 
Mechanisms of Tip110 function in Tat-mediated LTR transactivation 
What might be the actual mechanism by which Tip110 facilitates Tat transactivation? 
Firstly, overexpression of Tip110 significantly increased the viral gene expression and 
viral replication; this enhancement might due to the role of Tip110 in LTR transactivation 
by stimulating Tat-induced RNAPII phosphorylation.  Secondly, Tip110 formed a 
complex with Tat, unphosphorylated RNAPII CTD, and was detected on the LTR 
promoter in the absence of Tat.  Moreover, P-TEFb in the transcriptional complex was 
greatly increased in the presence of Tip110 and Tat.  On the basis of these observations, 
we proposed a working model of the function of Tip110 in Tat-mediated LTR 
transcription (Fig. 37).  Tip110 was first recruited to the LTR promoter independently 
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Figure 37. A working model for Tip110 function in HIV-1 LTR transactivation 
1. When unphosphorylated form of RNAPII is blocked with NELF and DSIF, Tip110 is 
first recruited to the LTR promoter, and bound to unphosphorylated RNAPII.  2. At the 
LTR promoter, Tip110 forms a complex with unphosphorylated RNAPII and the newly 
translated Tat protein.  Tip110 recruits more cyclin T1 and CDK9 to the transcription 
complex.  3. When RNAPII serine 2 is fully phosphorylated, LTR transcription 
elongation step starts and the full-length HIV-1 mRNA is produced.  At this step, Tip110 
leaves the hyperphosphorylated form of RNAPII to start a new round of transactivation.  
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with Tat.  It formed a complex with unphosphorylated RNAPII and Tat and recruited 
more cyclin T1 and CDK9 to the transcriptional complex, which would further enhance 
the RNAPII serine 2 phosphorylation.  When RNAPII serine 2 was fully phosphorylated, 
LTR transcription elongation would start and the full-length mRNA would was 
synthesized.  At this stage, Tip110 was about to leave the hyperphosphorylated form of 
RNAPII and would be recycled to start a new round of transactivation. 
 
However, we cannot rule out the possibilities that Tip110 regulates HIV-1LTR 
transcription via other transcription factors.  A separate study from our group has 
showed that Tip110 interacted with YB-1, a cellular ssDNA/RNA binding protein that 
interacts with both Tat and TAR and increases the level of Tat: TAR association (Sawaya, 
Khalili et al. 1998; Ansari, Safak et al. 1999).  Tip110, together with YB-1, has been 
shown to greatly increase LTR transactivation (manuscript in preparation), which implies 
that the interaction of Tip110 and other transcription factor may also contribute to Tip110 
effects in Tat-mediated transcription. 
 
Also, it will be important to compare the results obtained here in 293T cells with the 
more complex transcription factor interactions that occur on the native HIV-1 genome in 
activated T cells, where both initiation and elongation are further up-regulated by 
enhancer factors such as NF-κB and NF-AT.  Because our experiments were designed to 
analyze the transcription factors that are most directly involved in Tat transactivation, 
these results should provide a useful comparative framework for similar studies based on 
the induced viral genome in activated T cells.  
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The role of Tip110 in HIV-1 alternative splicing 
Pre-mRNA splicing is coupled to RNAPII transcription elongation.  Many splicing 
factors have shown to play a role in HIV-1 transcription elongation.  Therefore, we 
examined whether Tip110 plays a role in HIV-1 alternative splicing.  Using the 
multiplex PCR, we obtained the first evidence that Tip110 altered the HIV-1 mRNA 
splicing pattern (Fig. 23).  Normalized to the equal amount of GAPDH transcripts, one 
product that was derived from tat exon 2 showed an increase intensity (Fig. 23).  Four 
tat transcripts are generated from HIV-1 mRNA splicing and all contain tat exon 2 (Fig. 
4).  So we further performed RT-PCR to check which specific form of tat transcripts is 
increased by Tip110.  The primer TAR 5’ and Tat 21 spanned from the end of tat exon 1 
to the beginning of tat exon 2 (Fig. 24A), so we expected to see multiple bands according 
to the inclusion and exclusion of introns between exon1 and 2 in different tat transcripts.  
However, due to the predominant amount of tat 1 transcript in cells, only one single band 
was amplified by TAR 5’/Tat 21(Fig. 24C), and this transcripts showed 1.6-fold increase 
in the presence of Tip110.  
 
As Tat plays an important role in virus replication, it would be conceivable to speculate 
that HIV-1 has evolved a regulatory mechanism for an appropriate level of Tat expression.  
The major tat transcripts contain 3 exons.  The exon 2 is spliced between site A3 and D4, 
its splicing is mainly controlled by ESS2 splicing silencer and ESE2 enhancer (Si, 
Amendt et al. 1997), and partly regulated by ESS2p located upstream of ESS2 (Jacquenet, 
Mereau et al. 2001).  Exons 2-3 splicing is regulated by ESS3 and ESE3 located in tat 
exon3 (Tange, Damgaard et al. 2001).  The traditional method to test tat splicing 
162 
 
efficiency is to perform in vitro splicing assay with 32P-labled splicing RNA substrate (Si, 
Amendt et al. 1997; Si, Rauch et al. 1998).  In this study, we designed a tat minigene 
under the control of the CMV promoter and performed RT-PCR of the spliced and 
unspliced RNA to monitor in vivo RNA splicing.  This new method allowed us to 
determine the in vivo relationship between Tip110 expression and the tat minigene.  The 
results showed that Tip110 specifically increased tat exon1-2 splicing but had no effects 
on tat exons 2-3 splicing (Fig. 26 &27).  Since tat exon 2 splicing between A3 and D4 
splice sites is specifically for tat transcripts, while exon 3 splicing from A7 splice site is 
shared by all the multiply spliced transcripts, Tip110 specific activation on A3 splice site 
could explain why Tip110 preferentially increased tat transcripts but not rev or vpr 
mRNAs.  
 
The interaction between Tip110 and hnRNPA1 
A separate study from our group demonstrated that Tip110 forms a complex with hnRNP 
A1 (Table 2).  We confirm this interaction both in vivo and in vitro in this study (Fig. 33 
& 34).  hnRNP A1 has been demonstrated as the major regulator of HIV-1 pre-mRNA 
site A3 splicing.  It binds to ESS2 cis-element in tat exon 2, blocks the association of 
U2AF35 and inhibits early step of spliceosome assembly (Si, Amendt et al. 1997; Caputi, 
Mayeda et al. 1999).  Thus, for A3 activation, hnRNP A1 has to be dissociated from 
ESS2, followed by SC35 or SRp 40 binding to ESE2 (Ropers, Ayadi et al. 2004; Hallay, 
Locker et al. 2006).  Thus, we speculate that Tip110 may function in HIV-1 A3 site 
activation through its interaction with hnRNP A1.  However, the interaction between 
hnRNP A1 and Tip110 could be only in an enrichment assay, but not by the routine 
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IP/WB method (Fig. 34).  The discrepancy might be result from that the antibodies for 
immunoprecipitation; or that in vivo interaction between Tip110 and hnRNP A1 might be 
weak or transient; or thatTip110 competed with other protein for hnRNP A1 binding. 
 
Further study is clearly needed to identify the domains of hnRNP A1 and Tip110 that are 
directly involved in the Tip110/hnRNP A1 interaction.  As the C-terminal Gly domain of 
hnRNP A1 mediates the interaction between hnRNP A1 and different RNA-binding 
proteins (Cartegni, Maconi et al. 1996) and HAT domain is important for Tip110 protein 
interaction (Harada, Yamada et al. 2001; Liu, Li et al. 2002), we speculated that the 
N-terminal HAT domain of Tip110 and the C-terminal Gly domain of hnRNP A1 might 
be involved in the Tip110/hnRNP A1 interaction.  Moreover, the interaction between 
Tip110 and hnRNP A1 might inhibit hnRNP A1 association with ESS2, as hnRNP A1 
forms a stable complex with ESS2 element through its C-terminal Gly domain (Zahler, 
Damgaard et al. 2004).  
 
The mechanisms of Tip110 function in regulating tat mRNA splicing 
Tip110 was first identified as a splicing factor that specifically binds to U6 and was 
required for U4/U6 annealing recycling (Gu, Shimba et al. 1998; Bell, Schreiner et al. 
2002).  Therefore, we first hypothesized that Tip110 enhanced tat exons 1-2 splicing by 
accelerating snRNP recycling and promoting spliceosome assembly at splice site A3.  
Although Tip110 contains two RRM domains, it does not interact with either ESS2 or 
ESE2 element in tat exon 2 (Fig. 35).  Surprisingly, when we determined if hnRNP A1 
mediated Tip110 effect on A3 splice site activation, we found that Tip110 blocked the  
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Figure 38. A working model for Tip110 function in HIV-1 3'ss A3 activation 
 
1. The multimerization of hnRNP A1 to the ESS2 masks the binding site of SC35 on 
ESE2, inhibits the association of U2AF35 to the A3 splicing site, and further blocks the 
U2AF65 to the PPT site.  Thus, the early step of spliceosome assembly is inhibited and 
A3 splicing site is inactivated.  2. In the presence of Tip110 protein, Tip110 directly 
binds hnRNP A1 and blocks the binding site of hnRNP A1 to ESS2 element, results in the 
dissociation between hnRNP A1 and ESS2.  Then, SC35 or SRp40 protein will bind to 
ESE2 element; increase the U2AF binding efficiency to the PPT.  These SR proteins 
counteract the negative effect of hnRNP A1 and activate the A3 splice site.   
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hnRNP A1 interaction with ESS2 element (Fig. 36).  Based on these observations, we 
speculated that hnRNP A1 was first recruited to theESS2 cis-element (Fig. 38).  The 
multimerization of hnRNP A1 at the ESS2/ESE2 masks the SR protein binding site 
within ESE2, inhibits the association of U2AF35 to the A3 splicing site, blocks the 
U2AF65 to the PPT Site, and eventually inhibits the association of U2snRNP with the 
branch site.  Therefore, the early step of the spliceosome assembly is inhibited and A3 
splice site is inactivated.  In the presence of Tip110, Tip110 binds to hnRNP A1 and 
blocks the binding site of hnRNP A1 from ESS2 element.  This will trigger the 
dissociation of hnRNP A1 withESS2 cis-element, which will further expose the ESE2 
cis-element and recruit SC35 or SRp40 to the ESE2.  Binding of SR proteins will 
counteract the negative effect of hnRNP A1 by increasing U2AF binding efficiency to the  
PPT and activating the A3 splicing site.   
 
However, Tip110 may also activate the tat A3 splicing through other splicing factors.  It 
has been reported that Tip110 binds to RNPS1 and stimulates the proximal alternative 3’ 
splicing of calcitonin-dhfr pre-mRNA minigene with RNPS1 and RNPS1 itself has been 
shown to activate tat minigene splicing (Mayeda, Badolato et al. 1999; Harada, Yamada 
et al. 2001).  Also, our group has identified that Tip110 interacted with YB-1 protein and 
increased CD44 alternative splicing (manuscript in preparation).  But YB-1 function in 
splicing has not been applied to HIV-1 alternative splicing.  Thus, further study would 
explore whether Tip110 interaction with RNPS1 or YB-1 would have any effects on 
HIV-1 alternative splicing.  Also, the tat minigene used in this study is driven by CMV 
promoter instead of HIV-1 LTR promoter, it will be interesting to learn whether Tip110 
interaction with HIV-1 LTR promoter in vivo will help to recruit other spliceosome 
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components, such as U4 and U6 snRNP to the full-length pre-mRNA and further activate 
HIV-1 alternative splicing.  
 
Tip110 function in HIV-1 transcription and pre-mRNA splicing 
Eukaryotic pre-mRNA splicing is tightly coupled to transcription, mainly through 
phosphorylated RNAPII CTD, which interacts with a numbers of splicing factors 
(Mortillaro, Blencowe et al. 1996; Kim, Du et al. 1997; Ge, Si et al. 1998).  Cellular 
factors Tat-SF1, CA150 and SKIP have been reported to function in both transcription 
and alternative splicing in HIV-1 gene expression and replication.  Tat-SF1 is required 
for efficient transcriptional transactivation by binding to P-TEFb and also interacts with 
spliceosomal components.  The TAT-SF1-snRNP-containing couple complex stimulates 
transcription as well as promotes splicing (Zhou and Sharp 1996).  CA150 is a 
transcription-splicing coupling factor and inhibits Tat-mediated HIV-1 viral transcription 
through its interaction with splicing factors and RNAPII (Zhou and Sharp 1996; Fong 
and Zhou 2000; Kameoka, Duque et al. 2004).  Therefore, the function of Tat-SF1 and 
CA150 in HIV-1 transcription elongation and alternative splicing is coupled.  SKIP 
interacts with Tat:P-TEFb complexes, acting through nascent RNA to overcome pausing 
by RNAPII. It also interacts with U5snRNP proteins and tri-snRNP110K and facilitates 
recognition of an alternative Tat-specific splice site in vivo.  However, U5snRNPs 
recruit to SKIP only within transcribed regions instead of LTR, indicating SKIP activates 
HIV-1 transcription independently of the U5snRNPs, and engages in transcription and 
splicing process at different transcription elongation stages (Vaness Bres Nathan Gomes 
and Jones 2005). 
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Tip110 regulates both Tat-mediated LTR transcription and HIV-1 alternative splicing and 
has positive effect on HIV-1 gene expression and viral replication.  However, our study 
suggested that Tip110 is recruited to the LTR promoter and released from phosphorylated 
RNAPII when transcription elongation starts.  Therefore, Tip110 would not stay with 
phosphorylated RNAPII throughout the transcription process.  However, Tip110 has to 
be relocated to tat exon2and regulate tat mRNA splicing at A3 splice site for its splicing 
effect, indicating that Tip110 functions in transcription and splicing are spatially and 
temporally regulated.  Moreover, in the in vivo splicing assay, the tat minigenes are 
driven from the CMV promoter rather than the LTR promoter; and Tat, which is critical 
for Tip110 function in transcription, is not expressed in 293T cells that were used in these 
studies.  Based on these observations, Tip110 may engage transcription and splicing 
complexes in different stages in the elongation process.  On the other hand, Tip110 
function in HIV-1 transcription elongation and splicing process is not completely 
independent.  Our data suggested that Tip110 enhanced Tat expression through 
alternative splicing, which would in turn binds to Tip110 to recruit more P-TEFb to the 
LTR promoter.  With the direct effects on LTR transcription elongation, Tip110 and Tat 
will help to produce more full-length mRNA for alternative splicing.  Thus, Tip110 
provides a positive feedback in Tat protein expression by HIV-1 RNA splicing and HIV-1 
LTR transactivation in HIV-1 gene expression and virion replication. 
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PERSPECTIVE 
 
Since the introduction of HAART therapy in 1990’s, the AIDS pandemic has been 
changed from a uniformly fatal disease to a chronic disease.  However, HARRT cannot 
eradicate the virus from the body and there are still latent virus reservoirs.  Moreover, 
even though HAART can reduce viral replication to undetectable levels, active viral 
replication is continuing in lymphoid tissue of the gut.  The cost of these drugs has been 
a significant burden to both individuals and governments.  For these reasons, alternative 
treatments for HIV-1 infection are being studied and understanding the mechanism of 
HIV-1 replication in host cells will help to develop new anti-HIV therapeutic strategies.  
 
As our understanding of the HIV pathogenesis increases, HIV-1 Tat has become the key 
determinants in disease progression.  Peptide analogs of Tat have been shown to stop the 
recruitment of cdk2 to the LTR, decrease transcription and viral load in a small animal 
model of HIV-1 infection (Van Duyne, Cardenas et al. 2008).  Other small molecular 
inhibitors have also been developed to disrupt the Tat-TAR interaction, but none has been 
moved into clinical trials (Riguet, Desire et al. 2005).  Since there are no therapies 
directly targeting individual Tat, the host factors that regulate Tat expression are potential 
targets for new HIV-1 therapeutics.  
 
On the other hand, HIV-1 alternative splicing offers several approaches for combating 
HIV-1 infection.  HIV-1 splicing is regulated by the interaction between RNA 
cis-element and splicing factors and this RNA: protein interaction provides two types of 
therapeutic targets.  One approach is to mask RNA sequences with antisense strategy to 
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block the use of viral splice sites (Asparuhova, Marti et al. 2007).  Another method is to 
modify the expression level of SR protein or hnRNP protein by RNA interference, which 
needs further work to find safe delivery systems.  Therefore, new approaches targeting 
HIV-1 regulatory elements at transcription and splicing, in combination with traditional 
antiviral strategies, may provide a new tool for fighting against HIV/AIDS. 
 
Possible role of Tip110 in HIV-1 transcription initiation 
In this study, we focused on the mechanism of Tip110 function in Tat-mediated 
transcription elongation, and the results showed that Tip110 was able to recruit P-TEFb to 
the LTR, increase the serine 2 phosphorylation which further enhanced the transcription 
elongation.  However, Tip110 showed to increase the luciferase activity controlled by 
LTR promoter (Fig. 7) and Tip110 could increase RNAPII serine 5 phosphorylation level 
(Fig. 17), indicating that Tip110 may also activate LTR transcription initiation in the 
absence of Tat.  Since Tip110 is recruited to the LTR promoter independently of Tat and 
bound to unphosphorylated RNAPII, it may recruit CDK7/cyclin H to the 
unphosphorylated RNAPII, which further accelerate the RNAPII promoter clearance step 
and enhance the transcription initiation.  To test this hypothesis, additional studies are 
needed to determine if there is an interaction between Tip110 and CDK7/cyclin H, 
followed by ChIP assay to determine if more CDK7 and cyclin H are recruited to the 
integrated LTR promoter and associated with increased RNAPII serin 5 phosphorylation 
in the presence of Tip110.   
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Role of Tip110 in HIV-1 replication in T cells 
HIV-1 requires activation of T cells for viral replication.  In memory T cells, HIV-1 
stays latent for months to years, and the absence of Tat marks one form of proviral 
latency, when only short transcripts are produced.  Upon stimulation of the cells by 
TNF-α, NF-kB and TFIIH are rapidly recruited to the LTR promoter with additional 
mediators and RNAPII.  Because Tip110 interacts with unphosphorylated RNAPII and 
is recruited to the LTR promoter, it is reasonable to speculate that Tip110 is required for T 
cell activation.  To determine the role of Tip110 during HIV-1 reactivation in T cells, 
further experiments should be performed in Jurkat cells containing integrated, but 
transcriptionally silent HIV-1 proviruses.  With the treatment of TNF-α, ChIP assay can 
be performed to examine if more NF-kB, TFIIH, TBP and RNAPII are recruited to the 
LTR in the presence of Tip110.  In addition, HIV-1 gene expression can be examined in 
activated T cells with constitutive and reduced level of Tip110.  These data will address 
the relationship between Tip110, T cell activation and HIV-1 LTR transactivation and 
help us to understand how cellular activation signals activate latent HIV-1 in T cells.  
 
Role of Tip110 in singly spliced mRNA splicing 
Using multiplex PCR, we showed that Tip110 altered the HIV-1 splicing profile of 
multiply spliced mRNA (Fig. 23).  But the role of Tip110 in HIV-1 singly spliced pattern 
was still unclear.  As HIV-1 splicing is delicately balanced, more multiply spliced 
transcripts would result in less singly spliced/unspliced mRNA.  It has been shown that 
SR proteins SC35 and 9G8 increase tat mRNA production and decrease single spliced 
products such as vpr and env mRNA and cause a large reduction of genomic RNA 
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(Jacquenet, Decimo et al. 2005).  In order to determine the Tip110 effects in singly 
spliced mRNA production, multiplex PCR with primers GAGA and KPNA specific for 
singly spliced or unspliced RNA should be performed with HIV-1 RNA isolated from 
Tip110 expressing cells (Markus Neumann 1994).  The important next step is to 
determine if the expression level of structural proteins such as Vpr, Env and Gag will be 
altered by Tip110 through splicing.  In addition, it would be interesting to determine if 
Tip110 would delay new virus maturation by altering structural protein expression. 
 
Tip110 function in transcription and splicing 
 
As previously discussed, we obtained several lines of data suggesting that Tip110 
function in HIV-1 transcription elongation and alternative splicing is uncoupled.  To 
further determine this possibility, in vitro splicing assay with the same amount of tat 
mRNA in vitro transcribed from tat minigene should be performed.  These experiments 
would allow us to evaluate Tip110 effect on tat minigene mRNA splicing without 
transcriptions.  To determine whether Tip110 splicing function is unnecessary for 
transcription, in vitro transcription/elongation assay could be performed with hnRNP 
A1-depletednuclear extract to determine if Tip110 interaction with hnRNP A1 is involved 
in HIV-1 transcription elongation.  In addition, ChIP assay could be performed to 
determine whether hnRNP A1 would be recruited to the LTR promoter with Tip110.  
These experiments will be very informative for determining whether Tip110 function in 
HIV-1 transcription elongation and alternative splicing is coupled or not. 
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Tip110 as a novel anti-HIV target 
Tat is considered to be the major HIV-1 transcription transactivation factor; therefore, it is 
conceivable that suppression of Tat expression by knocking down Tip110 may be able to 
complement the current anti-HIV therapies that are mainly targeted at HIV-1 protease and 
reverse transcriptase, providing a better treatment outcome.  To test this hypothesis, the 
efficacy of knocking down Tip110 to inhibit HIV-1 replication in an infected organism 
should be determined.  Humanized HIV-1 mouse model which recapitulates most of the 
immunological features in HIV-1 infected humans can be used for such studies (Sun, 
Denton et al. 2007).  The mice infected with HIV-1 could be treated with Tip110 siRNA 
or shRNA monitored for HIV-1 replication in these mice.  However, as the biological 
functions of Tip110 are not completely understood, any Tip110 knock-down based 
anti-HIV therapy should be only targeted at HIV-1 infected cells but not the normal cells.  
Therefore, further study has to address how to target the HIV-1 infected cells.  
Nevertheless, specific targeting of HIV-1 infected cells would be a huge challenge.  One 
potential solution is the inverse fusion strategy, that is to use vesicular stomatitis virus 
pseudotyped with HIV-1 receptor CD4 and a coreceptor, CXCR4 to infect HIV-infected 
cells (Mebatsion, Finke et al. 1997).  This strategy can be explored to deliver Tip110 
siRNA or shRNA into HIV-1 infected cells to knock down endogenous Tip110 expression 
in HIV-1 infected cells and subsequently control HIV-1 replication and the disease 
progression.   
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